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Summary
The European Food Safety Authority (EFSA) requested its Scientiﬁc Committee to prepare a
guidance document providing generic issues and criteria to consider biological relevance, particularly
when deciding on whether an observed effect is of biological relevance, i.e. is adverse (or shows a
beneﬁcial health effect) or not.
The guidance clariﬁes a number of deﬁnitions and concepts (such as, responses of a biological
system to exposure, mode of action and adverse outcome pathways, thresholds, critical effect,
modelling approaches, biomarkers), which are central to biological relevance, in order to achieve that
these concepts are used in a consistent way across EFSA areas of activity.
The list of generic issues (e.g. nature and size of the biological changes or differences, including
the relevance of the biological systems where the effects are observed) to consider when deciding on
whether an observed effect is biologically relevant should be applicable to all relevant EFSA Scientiﬁc
Panels and Scientiﬁc Committee.
A framework was developed in which biological relevance is considered at three main stages related
to the process of dealing with evidence. Development of the assessment strategy, should specify agents,
effects, subjects and conditions in relation to the assessment question(s). The collection and extraction
of data should follow identiﬁcation of potentially biologically relevant evidence/data as speciﬁed in the
Assessment strategy. The third step should include an appraisal and an integration of the biological
relevance for each data set of the agents, subjects, effects and conditions. With regard to the agent, it
should be considered whether the assessment is based on the agent of concern or on a surrogate agent.
It should be considered whether the study is based on the subjects of concern (e.g. for human studies in
humans) or in case proxies (e.g. animal models for humans) are used whether effects occurring are
biologically relevant for the subject of concern. For the effects, consideration should be given as to
whether the effect is causally related to exposure to the agent. The nature of the effect should be taken
into account, i.a. homeostatic response, adaptive, adverse/beneﬁcial or directly or indirectly linked to an
adverse/beneﬁcial effect. Finally, for effects, it should be assessed whether the magnitude of the effect
is sufﬁcient to be of biological relevance (e.g. outside normal variation, and for effects directly or
indirectly linked to an adverse/beneﬁcial effect whether they are of sufﬁcient magnitude to result in an
adverse/beneﬁcial outcome). It should be noted that the biological relevance of an effect can vary
according to the assessment question. For each data set, it should be considered whether the conditions
of the studies (environmental, toxicological, epidemiological, etc.) used for the assessment are relevant
for the conditions under consideration.
Each step of relevance considerations may be a source of uncertainty. The assessor should address
these uncertainties during the assessment process as a part of the general uncertainty analysis of the
assessment. Assessing biological relevance and associated uncertainty should be addressed and
reported as part of the weight of evidence assessment, and its guidance on reporting can be applied.
Several case studies covering the various EFSA areas are referred to in the guidance and annexed
to the opinion to illustrate how previous assessment may ﬁt the proposed approach.
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1. Introduction
1.1. Background and Terms of Reference as provided by EFSA
As per EFSA’s Founding Regulation (EC) No 178/2002 of the European Parliament and of the
Council, ‘the EFSA Scientiﬁc Committee shall be responsible for the general coordination necessary to
ensure the consistency of the scientiﬁc opinion procedure, in particular with regard to the adoption of
working procedures and harmonisation of working methods’. The EFSA Science Strategy 2012–2016
echoes this key responsibility of the Scientiﬁc Committee by setting the development and
harmonisation of methodologies and approaches to assess risks associated with the food chain as one
of the four strategic objectives for the European Food Safety Authority (EFSA).
The recent opinion of the Scientiﬁc Committee (SC) on ‘Priority topics for the development of risk
assessment guidance by EFSA’s Scientiﬁc Committee’ (EFSA, 2013a,b) gives recommendations for the
preparation of new or revision of existing guidance documents. The criteria for prioritising guidance
documents to be developed are:
• Across Panel Relevance
• Critical importance including urgency of topic to be addressed for several Panels
• Topic not being addressed by an individual Panel
• Sufﬁcient information available to develop meaningful guidance
• International dimension.
The development of guidance on biological relevance was identiﬁed by the EFSA SC as one of the
three high priority topics for 2014.
In the EFSA opinion on the hazard assessment of endocrine disruptors (EFSA Scientiﬁc
Committee, 2013), the concept of biological relevance assumes that a ‘normal’ biological state can
be deﬁned and the deﬁnition of normality is closely linked to adversity of an effect observed during
toxicity testing or in epidemiological studies. Distinguishing adverse effects from physiological
adaptive effects is not only crucial in identifying a No Observed Adverse Effect Level (NOAEL) from
experimental toxicity studies but also when using the benchmark dose (BMD) approach as
recommended by the SC (EFSA Scientiﬁc Committee, 2017).
In its opinion on biological relevance vs statistical signiﬁcance, the EFSA SC gave a wider deﬁnition
of biological relevance than just a modiﬁcation of a physiological system, making it more applicable to
the various EFSA working areas. In that opinion, biological relevant effect is deﬁned as an effect
considered by expert judgement as important and meaningful for human, animal, plant or
environmental health. It implies a change that may alter how decisions for a speciﬁc problem are
taken (EFSA Scientiﬁc Committee, 2011a,b). Different EFSA guidance documents are also addressing
expert judgement approaches (EFSA, 2014a, 2017).
The above deﬁnition implies that guidance is provided to the various EFSA panels on what ‘harm’
means, and to deﬁne a number of related concepts such as ‘effect size’. When a particular risk
assessment considers several effects, the overall picture, using a multivariate approach, should be
considered to decide whether the available body of knowledge allows to conclude on an effect to be
adverse or not. Given the broad remit of activity of EFSA, the purpose of this self-task mandate is to
provide the Scientiﬁc Panels with generic issues to consider when discussing on biological relevance,
i.e. being adverse (or showing a beneﬁcial health effect) or not.
Terms of Reference
EFSA requires its SC to prepare a guidance document providing generic issues and criteria to
consider when deciding on whether an observed effect is of biological relevance, i.e. is adverse (or
shows a beneﬁcial health effect) or not.
The opinion should clarify a number of deﬁnitions and concepts, such as, adverse, adaptive, harm,
homeostasis, biological threshold in order to achieve that these concepts are used in a consistent way
across EFSA areas of activity.
The list of criteria/generic issues (e.g. nature and size of the biological changes or differences) to
consider to decide whether an observed effect is biologically relevant should be applicable to all
relevant EFSA Scientiﬁc Panels and Scientiﬁc Committee.
Several case studies covering the various EFSA areas will be annexed to the opinion to illustrate the
proposed approach.
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Links should be established with related ongoing EFSA activities, particularly with the SC working
group on weight of evidence, the activity of the Assessment and Methodological Support (AMU) Unit
on promoting methods for evidence use in scientiﬁc assessments (PROMETHEUS), and the SC working
group on uncertainty in risk assessment. Relevant international activities and developments in the
area, such as the IPCS/WHO mode of action framework should also be considered.
In view of the horizontal aspect of this topic and the need to get a common agreement and
understanding of what biological relevance means, representatives of EFSA sister agencies, European
Commission non-food committees and international bodies (e.g. WHO) should be invited to participate
in the working group.
1.2. Interpretation of the Terms of Reference
When addressing the mandate, the SC acknowledged that the issue of biological relevance in risk
assessment has a broader meaning than biologically relevant effect as described in the Terms of
Reference. In fact, it encompasses also aspects related to the deﬁnition of the problem formulation.
This, in turn, guides the development of the assessment strategy, which includes the decision on which
data to use for the assessment (relevance of the data).
Aspects related to the reliability of the various pieces of evidence used in the assessment are
outside the scope of this mandate, as they are the subject of another SC guidance on weight of
evidence (EFSA, 2017).
The purpose of this document is to discuss and provide guidance across Panels/Units of EFSA on
the above-mentioned issues and how they should be addressed during the risk assessment process.
1.3. Relation to other relevant EFSA guidance documents
The guidance on the use of the weight of evidence (EFSA, 2017) builds on the conceptual approach
for scientiﬁc assessments as described in PROMETHEUS (EFSA, 2015a), which describes the overall
process for dealing with data and evidence. The process has four steps as shown in Figure 1 and
biological relevance may need to be assessed in every step:
Transparent reporting of all assumptions and methods used, including expert judgement, is
necessary to ensure that the assessment process leading to the conclusions is fully comprehensible.
‘Open EFSA’ aspires both to improve the overall quality of the available information and data used
for its scientiﬁc outputs and to comply with normative and societal expectations of openness and
transparency (EFSA, 2009a, 2014a–e). In line with this, EFSA is publishing three separate but closely
related guidance documents to guide its expert Panels for use in their scientiﬁc assessments (EFSA,
2015a). These documents address three key elements of the scientiﬁc assessment: the analyses of
Uncertainty, Weight of Evidence and Biological Relevance.
The ﬁrst document provides guidance on how to identify, characterise, document and explain all
types of uncertainty arising within an individual assessment for all areas of EFSA’s remit. The Guidance
does not prescribe which speciﬁc methods should be used from the toolbox but rather provides a
Figure 1: The process for dealing with data and evidence when conducting an assessment (EFSA,
2015a)
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harmonised and ﬂexible framework within which different described qualitative and quantitative
methods may be selected according to the needs of each assessment.
The second document on weight of evidence provides a general framework for considering and
documenting the approach used to evaluate and weigh the assembled evidence when answering the
main question of each scientiﬁc assessment or questions that need to be answered in order to provide,
in conjunction, an overall answer. This includes assessing the relevance, reliability and consistency of
the evidence. The document further indicates the types of qualitative and quantitative methods that
can be used to weigh and integrate evidence and points to where details of the listed individual
methods can be found. The weight of evidence approach carries elements of uncertainty analysis: that
part of uncertainty which is addressed by weight of evidence analysis does not need to be reanalysed
in the overall uncertainty analysis, but may be added to.
This document provides a general framework to addresses the question of biological relevance at
various stages of the assessment: the collection, identiﬁcation, and appraisal and integration of
relevant data for the speciﬁc assessment question to be answered. It identiﬁes generic issues related
to biological relevance in the appraisal of pieces of evidence, in particular, and speciﬁc criteria to
consider when deciding on whether or not an observed effect is biologically relevant, i.e. adverse (or
shows a beneﬁcial health effect). A decision tree is developed to aid the collection, identiﬁcation and
appraisal and integration of relevant data for the speciﬁc assessment question to be answered. The
reliability of the various pieces of evidence used and how they should be integrated with other pieces
of evidence is considered by the weight of evidence guidance document (EFSA, 2017).
EFSA will continue to strengthen links between the three distinct but related topics to ensure the
transparency and consistency of its various scientiﬁc outputs while keeping them ﬁt for purpose (Figure 2).
1.4. Audience and degree of obligation
This Guidance is aimed at all those contributing to EFSA assessments and provides a harmonised,
but ﬂexible framework to determine biological relevance that is applicable to all areas of EFSA’s work
and all types of scientiﬁc assessment. In line with improving transparency (EFSA, 2006, 2009a) and
reporting (EFSA 2014b, 2015a), the SC considers the application of this guidance to be unconditional
for EFSA. Each assessment must clearly and unambiguously document:
• what evidence was considered;
• how the evidence was weighed and integrated in terms of relevance.
The document provides guidance on the general principles to determine the biological relevance
but assessors have the ﬂexibility to choose the degree of reﬁnement in applying them. The SC
considers that these should be ﬁt for the purpose of the scientiﬁc assessment.
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Figure 2: Relationship of relevance (including biological relevance), reliability and consistency to the
three basic steps of weight of evidence assessment and to the conclusion for a weight of
evidence question
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2. Data and methodologies
The process for dealing with data and evidence in an assessment as deﬁned in the PROMETHEUS
project deliverable 1 (EFSA, 2015a) was used as a framework for developing a guidance on biological
relevance. A fundamental step in this process is represented by planning a strategy for the assessment
including:
• the problem formulation;
• the conceptual framework;
• the deﬁnition of the evidence needs; and
• the approach for:
 Collecting or extracting relevant data; Validating or appraising evidence; Analysing and integrating evidence.
In line with the ‘Open EFSA’ objective (i) to improve the overall quality of available information and
data used for its outputs and (ii) to comply with normative and societal expectations of openness
(EFSA, 2014b, 2015a), a targeted consultation of national and international scientiﬁc advisory bodies
was organised on an EFSA Journal editorial presenting ‘Increasing robustness, transparency and
openness of scientiﬁc assessments’ and a document providing the individual background and terms of
reference of four related activities:
• the PROMETHEUS (‘PROmoting METHods for Evidence Use in Scientiﬁc assessments’) project
which aims to further improve the methods for ‘dealing with data and evidence’ (i.e.
collecting/extracting, validating/appraising, analysing and integrating data and evidence) in
EFSA scientiﬁc assessments and to increase their consistency.
• Three topics for guidance developments: (i) the identiﬁcation of biological relevance of
adverse/beneﬁcial health effects from experimental animal and human studies; (ii) the use of
the weight of evidence in scientiﬁc assessments; (iii) the characterisation of uncertainties in
scientiﬁc assessment.
A workshop was then organised on 29 and 30 June 2015 in Brussels to consult with national and
international bodies including European Agencies, European Commission Scientiﬁc Committees,
national agencies and international bodies with an interest in biological relevance. One objective of the
workshop was to present the terms of reference of the two SC working groups on weight of evidence
and biological relevance, clarify the objectives and the scope of the resulting guidance documents, and
capture from the audience relevant work that should be considered by the working groups when
drafting the guidance.
A Working Group composed of Panel Experts and EFSA Staff representing all EFSA areas of activity
was created to address the above mandate. Members of the working group were ﬁrst asked to
describe in short documents how biological relevance was considered in past assessments (see
Annexes). Key concepts and deﬁnitions that came out of these examples or that came out from the
above consultations and that one should have in mind when considering the relevance of a data set or
a piece of evidence for an assessment, have been organised into a conceptual framework and are
further described in the following sections.
3. Biological Relevance – Related Concepts and Assessment
Framework
The assessment strategy should specify which scientiﬁc evidence (data) would be relevant for
answering the assessment question(s). However, relevance can only be determined if the question(s)
for assessment is well-deﬁned. It is therefore important to ensure a clear understanding and
interpretation of the question(s) for assessment between the risk assessors and with the risk manager
before developing the assessment strategy.
Having clarity on the assessment question(s) would provide guidance on how to decide which data
are relevant. This is important because it identiﬁes at an early stage what should be included or can
be excluded from the assessment: which effects, which data, which model, which parameters, etc.
Note that if an endpoint has relevance, then all studies testing for that particular endpoint become
relevant, as both positive and negative ﬁndings may inﬂuence the answer to the assessment question.
Biological Relevance in Scientiﬁc Assessment
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When the relevant data have been collected, the biological relevance of the effects in each data set
should then be appraised.
It is important to note that the reliability of the various pieces of evidences used and how they should
be integrated with other pieces of evidence in the assessment are outside the scope of this SC guidance
on relevance, as these are the subject of another SC guidance on Weight of Evidence (EFSA, 2017).
In the following text, some fundamental concepts related to biological relevance will be presented
followed by a framework for consideration of relevance. This includes considerations to be done at the
three steps:
• Development of the assessment strategy, in this context, speciﬁcation of agents, effects,
subjects and conditions.
• Collection and extraction of data, i.e. identiﬁcation of potentially biologically relevant
evidence/data as speciﬁed in the Assessment strategy.
• Appraisal and integration of the relevance of the agents, subjects, effects and conditions, i.e.
reviewing dimensions of biological relevance for each data set.
3.1. Concepts about biological relevance
In 2011, the SC expressed an opinion addressing the concept of Statistical Signiﬁcance and
Biological Relevance in the context of assessing scientiﬁc evidence. The following deﬁnition of
biological relevance was developed:
A biologically relevant effect can be deﬁned as ‘an effect considered by expert judgement as
important and meaningful for human, animal, plant or environmental health. It therefore implies a
change that may alter how decisions for a speciﬁc problem are taken’ (EFSA, 2011).
The guidance, in which this deﬁnition of Biological Relevance was developed, stressed that a
statistically signiﬁcant effect should not automatically be considered relevant for the outcome of an
assessment, but that an independent evaluation of the effects as to its relevance was required. In this
context, the deﬁnition implies that all effects that directly or indirectly would have the potential to
inﬂuence the outcome of the assessment should be considered.
3.1.1. About responses of a biological system to exposure
A biological system usually reacts to signals from its environment, including the agent (e.g.
chemical substance, nutrient, microorganism, pathogen or invasive species) under assessment. The
quality of the response of the biological system, hereafter called the nature of the effect, can be either
adverse, adaptive or beneﬁcial and may occur at different levels, e.g. molecular, cell, organ,
individual, population or ecosystem.
Adverse effects
An effect is considered ‘adverse’ when leading to a change in the morphology, physiology, growth,
development, reproduction or life span of an organism, system or (sub)population that results in an
impairment of functional capacity to compensate for additional stress or an increase in susceptibility to
other inﬂuences (WHO, 2009).
The SC acknowledges that this deﬁnition is very broad and that the relationship between the
measured endpoint and the change in the functional capacity may be difﬁcult to establish. The
following text aims to provide some guidance on assessing adversity in the context of biological
relevance of an effect.
An adverse effect might be primary (directly induced by the agent) or secondary (e.g. related to
stress or nutritional imbalance induced by the agent) (Lewis, 2002). It is important to distinguish this
for the interpretation of the effect in the context of the assessment question.
Reversibility and recovery
Adverse does not necessarily mean irreversible. An adverse change might be reversible. Whether
adverse ﬁndings are reversible can be evaluated in an animal test model if animals are allowed to recover
after an appropriate non-dosing period. For example, adverse changes in regenerating tissues can
recover (effects on spermatogenesis can lead to the non-function of the genital system and lack of the
possibility to reproduce; but recovery can happen after a withdrawal of the exposure) (Perry et al., 2013).
Biological Relevance in Scientiﬁc Assessment
www.efsa.europa.eu/efsajournal 9 EFSA Journal 2017;15(8):4970
In environmental risk assessment, the concept of environmental harm is used, which is deﬁned as
the measurable adverse change in a natural resource or the measurable impairment of a natural
resource service. It may occur directly or indirectly (European Commission, 2004), or as a measurable
(or otherwise observable) loss or damage that has adverse (and signiﬁcant) impact upon conservation
and sustainable use of biodiversity (CBD, 2010).
The concept of ‘recovery’ is also used in environmental risk assessment: the return of the perturbed
(ecological) endpoint (e.g. species composition, population density) to the window of natural variability
as observed in the undisturbed state of the (eco)system of concern (e.g. before the stressor event
took place), or to the level that is not signiﬁcantly different anymore from that in control or reference
systems. It should be noted that a system that has been subject to an adaptive response or to
recovery might not necessarily return to the same state that it exhibited before the disturbance (EFSA,
2016a–e).
It should be noted that between reversibility on the individual level and population recovery, there
is also population relevance. As an example, small effects on fecundity in density regulated systems
(e.g. ﬁsh reproduction with many more eggs than can possibly develop into juvenile ﬁsh) will not
translate to the population level; as there is no effect on the population level, there is no need for
recovery (e.g. Hamilton et al. 2014; https://doi.org/10.1186/1741-7007-12-1).
Homeostatic capacity
When subject to a disturbance, a biological system enters in a transient state: a process variable
has been changed and the system has not yet reached steady state. Some systems, including humans,
have the capacity to regulate their internal environment and to maintain a stable, relatively constant
condition of properties; it is called ‘homeostatic capacity’. Resilience represents the amount of
disturbance that can be absorbed by a system before the system changes or loses its normal function,
or the time taken to return to a stable state, within the normal operation range following the
disturbance (Gunderson, 2000). The homeostatic capacity varies. Reducing that capacity might be
detrimental, whereas increasing the capacity could be beneﬁcial. In order to assess homeostatic
capacity, a comprehensive analysis of multiple parameters (biomarkers) will have to be undertaken
(Pellis et al., 2012; Kardinaal et al., 2015).
Adaptive effects
The response to exposure to an agent can be ‘adaptive’, i.e. involving a process whereby a cell or
organism respond to an agent so that the cell or organism will survive in the new environment that
contains the agent without impairment of function (Keller et al., 2012). An adaptive response can be
an active regulation of a parameter to keep it within it physiological range, i.e. be a homeostatic
response (e.g. glycaemic regulation, body temperature regulation). Alternatively, an adaptive response
can occur outside physiological boundaries and may eventually become adverse; therefore, it requires
further considerations as to its adversity (e.g. composition of gut microbiota, liver enzyme induction).
This issue is also discussed in Annex I, regarding chemicals that may affect thyroid hormone
regulation).
Beneﬁcial effects
An effect is considered ‘beneﬁcial’ if it has the probability to be linked to a positive (health) effect
(e.g. increase the resilience of the organism to a certain challenge) and/or the probability to be linked
to a reduction of an adverse health effect in an organism, system or (sub)population, in reaction to
exposure to an agent (EFSA, 2016d). The relevance of biological outcomes in terms of beneﬁts follows
similar rules as those for adverse outcomes. Yet, it should be noted that for adverse outcomes, very
often data from animal test systems or in vitro studies are used. For (health) beneﬁts, studies on the
target species and population group are required, e.g. studies in humans in the case of health claims
for food, whereas studies other than in the target species, are used as supportive evidence (see
Annex G). In beneﬁt assessment, EFSA is normally with the exception of certain agricultural products
and processes (e.g. growth promotion of animals) not considering economic aspects. Such beneﬁts
may not necessarily be beneﬁcial for the health of the target species (see Annex E).
3.1.2. About Mode of Action and Adverse Outcome Pathway
When an agent (e.g. chemical) causes an adverse effect in an organism, the effect is often a result
of a sequence of events starting with a molecular interaction between the agent and the organism,
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which might differ between species. To what extent a molecular effect should be considered
biologically relevant in the target species depends on whether and how close it might be linked to an
adverse outcome in an appropriate test system, either as a key event or indirectly having an impact on
a key event in the in the sequence leading to an adverse outcome. Mode of Action (MoA) and Adverse
Outcome Pathway (AOP) are related concepts used in this context, although the latter is still in its
infancy.
The deﬁnition of MoA has evolved over time and derives from earlier works by the US EPA (1986,
2005) and the WHO. MoA analyses have been applied to a number of case studies for non-genotoxic
and genotoxic chemicals (Boobis et al., 2006, 2008a). The current WHO deﬁnition for MoA is ‘a
biologically plausible sequence of key events leading to an observed effect supported by robust
experimental observations and mechanistic data’. MoA describes key cytological and biochemical events
– that is, those that are both measurable and necessary to obtain the observed effect – in a logical
framework (Boobis et al., 2008a,b; WHO, 2009; Meek et al., 2014). In many cases, also the magnitude
of the effect might be critical for the determination of its biological relevance (see also Section 3.2.3).
In the US, MoA has been used as a term to reference a mechanistic understanding of the impact of
a chemical on human health. Toxicologists would also refer to the same concept using the terms
‘toxicity pathway, MoA, adverse outcome pathway or mechanism of action’ as used by the National
Research Council (NRC) report, Science and Decisions: Advancing Risk Assessment (2009) (NRC, 2009)
and the Nextgen report of the US-EPA (2013). Modiﬁed Bradford Hill criteria (Meek et al., 2014) can be
used to analyse the biological plausibility of key events and the weight of the related evidence.
Mechanism of action is deﬁned as the speciﬁc biochemical interaction through which a substance
produces an effect on a living organism or in a biochemical system (WHO/IPCS EHC 240). MoA does
not imply full understanding of mechanism of action, which refers to a detailed molecular description
of individual biochemical and physiological key events leading to a toxic effect (Boobis et al., 2008a,b;
WHO, 2009; EFSA, 2008).
Information from MoA can be used to establish AOPs. An AOP is deﬁned as the information on the
causal links between a molecular initiating event (MIE), intermediate key events (KEs) and an adverse
outcome (AO) of regulatory concern. ‘a sequence of events from the exposure of an individual or
population to a chemical substance through a ﬁnal adverse (toxic) effect at the individual level (from a
human health perspective) or population level (from an environmental perspective)’ (Ankley et al.,
2010; Meek et al., 2014; OECD, 2013). Such key events should be deﬁnable and make sense from a
physiological and biochemical perspective and in a toxicity pathway. Early key events including the MIE
have been deﬁned by the OECD as the ‘initial point of chemical–biological interaction within the
organism that starts the pathway’ (OECD, 2013). An example of developing an AOP can be found at
https://www.efsa.europa.eu/en/efsajournal/pub/4691.
Although not systematically developed for beneﬁcial effects, the concepts of MoA is applicable also
to beneﬁcial effect of an agent (e.g. chemical, nutrient or additive). Examples of this are use of
mechanistic and physiological information in the establishment of Dietary Reference Values (DRV) and
assessments of health claims on food and food ingredients (for examples see Annex G), and in efﬁcacy
assessments of feed additives (see Annex E).
Likewise, information on MoA, i.e. pathogenic mechanism, of a microorganism, pathogen or
invasive species are equally useful in the assessment of the effects of these types of agents (see e.g.
Annex C).
3.1.3. About thresholds
The term ‘threshold’ has a variety of different meanings, depending on the context in which this
term is used.
As a matter of principle, the absence of an effect can never be proven experimentally and thus the
existence of a ‘true’ threshold in the mathematical sense is not possible. The WHO (2009) deﬁnes
threshold as ‘Dose or exposure concentration of an agent below which a stated effect is not observed
or expected to occur’. The WHO deﬁnes the threshold dose as ‘The dose at which an effect just begins
to occur—that is, at a dose immediately below the threshold dose, the effect will not occur, and
immediately above the threshold dose, the effect will occur. For a given chemical, there can be
multiple threshold doses, in essence one for each deﬁnable effect. For a given effect, there may be
different threshold doses in different individuals. Further, the same individual may vary from time to
time as to his or her threshold dose for any effect. For certain chemicals and certain toxic effects, a
threshold dose may not be demonstrable. The threshold dose will fall between the experimentally
Biological Relevance in Scientiﬁc Assessment
www.efsa.europa.eu/efsajournal 11 EFSA Journal 2017;15(8):4970
determined no-observed-(adverse-)-effect level and the lowest-observed-(adverse-)effect level, both of
which have been used by different scientiﬁc groups as a surrogate for the threshold dose in the
performance of risk assessments’. Note that the EFSA SC recommends the use of the BMD approach
instead of the NOAEL for scientiﬁc assessment purposes (EFSA, 2017).
The WHO deﬁnition of a threshold dose indicates that there is no ﬁxed value for a threshold. This
applies both for the chemical as well as for the exposed individual. The discussion whether thresholds
(experimental, mathematical, biological or ‘true’) exist or not and at what level (biochemical, individual
or population level) does not solve the problem that when the dose decreases, the dose–response
curve becomes indistinguishable from the background response at a certain point and the shape of the
dose–response curve remains unknown thereafter as this dose range becomes experimentally
inaccessible or non-observable. This point is largely dependent on the nature and the design of the
study and its power to detect any effects. A biological threshold in this sense does not indicate a dose
below which any response is zero, but a dose, below which the response may be considered to be
biologically irrelevant provided sufﬁcient power of the study.
Furthermore, thresholds may be discussed at different levels, e.g. at the molecular, cell, organ,
individual, population or ecosystem level (Slob, 1999). It is important to note that chemical risk
assessment in the regulatory context usually addresses risks at the population level. Even if a
particular threshold would exist at a certain level (e.g. inhibition of a single enzyme molecule), it may
be different or even no longer exist at higher levels of biological systems (e.g. at the cellular level with
a population of enzyme molecules, at the organism level with populations of cells or at the level of
population of organisms) because the resulting dose response relationship is the result of a set of dose
response curves.
Thus, dose–response assessment is performed preferably in a probabilistic way (EFSA, 2017).
3.1.4. About critical effect
In toxicological risk assessment, the critical effect is deﬁned as the toxic or adverse effect occurring
at the lowest dose of an agent. The critical effect level is the dose at which the critical effect starts to
occur when increasing the dose and is linked to the size or magnitude of the effect, i.e. when it can be
identiﬁed. The determination of a critical effect size1 is strictly related to its natural background
variability, which might be determined using historical control data and when it becomes
distinguishable from the background variability.2
Ecotoxicological risk assessment is also often based on the toxic effect occurring at the lowest dose
or concentration. A proxy for the critical effect level in environmental risk assessment is the use of the
No Observed Effect Dose (NOED) or No Observed Effect Concentration (NOEC) for these effects, but
there are a number of exceptions (see Annex K).
Assuming that temporal ﬂuctuations in physiological parameters (e.g. haematology, biochemistry) in
individual healthy non-exposed animals are non-adverse, the minimal magnitude of the Critical Effect
Size (CES) fold change above background for a number of continuous parameters of toxicity studies
can be derived (Buist et al., 2009). If this background variability is exceeded, this can be considered as
a relevant effect size for this endpoint. The background variability of a parameter may differ between
individuals and between an individual and a population.
The size of an effect that would be considered biologically relevant should ideally be considered
before answering the assessment question. (see also EFSA, 2017, chapter 2.5.2). Once this has been
determined, a power analysis of key studies could be performed as this has implications on how the
reported effects and effect estimates from those studies are interpreted. Underpowered studies may
both fail to detect an effect with a relevant size and be more likely to inﬂate true effects or report
spurious effects (Ioannidis, 2005, 2008; La Caze and Duffull, 2011). In addition, it is important to keep
in mind that ‘Statistically signiﬁcant’ does not necessarily mean ‘important’, ‘meaningful’ or ‘biologically
relevant’ as it is sometimes misinterpreted. ‘Statistically signiﬁcant’ just means that the observed effect
size or difference is unlikely to have occurred by chance; it is a statistical statement on the property
and information content of the observed data (EFSA, 2011). In other words, a statistically signiﬁcant
effect may exist, but may be biologically irrelevant because, although statistically signiﬁcant, it is
smaller than the predeﬁned biologically relevant effect size, which can be deﬁned based on its
1 The term critical effect size may have different terminology, e.g. BMR or Limit of Concern (LoC), depending on the ﬁeld of
investigation.
2 If it is a biomarker and not an adverse effect in itself, exceedance of background variability may not be a sufﬁcient criterion to
decide on adversity.
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background variability. Conversely, lack of statistical signiﬁcance should not be the sole rationale for
concluding a lack of exposure related effect, just as statistical signiﬁcance should not be the sole
justiﬁcation for concluding on the occurrence of a treatment-related effect (OECD, 2007).
An example of an experiment where a statistical signiﬁcant treatment-related effect falls within the
variability of the historical control data according to prior knowledge and might be considered as
irrelevant for risk assessment, is given in Figure 3. The left point in Figure 3 is the mean value
observed in the control group. Note that in this case the control value is at the low end of the
background variability of the control group and although the middle point (value) is statistically
signiﬁcantly different from the control outcome, it is still within the background variability. Assuming
that the natural variability among the animals used in this study (Figure 3) was by chance low, then
when re-conducting the experiment, the variability would most likely be larger. The expected
consequences would be that the lowest exposed group may no longer be signiﬁcantly different from
the controls. In that case, the right, but not the mid-point, would be the Lowest Observed Effect
Concentration or Level (LOEC/LOEL).
Also, in the guidance document on toxicity endpoints from avian and mammalian reproductive
toxicity studies (EFSA, 2009c), it is mentioned that although the magnitude of an endpoint in an
exposed group could be statistically signiﬁcantly different from that of the controls, it might not be
biologically relevant. The following is a quote of this document: ‘In order to determine the biological
relevance of an effect it should be considered whether the effect could lead to a functional deﬁcit later
on in the study, e.g. if a reduction in the weight of pups at birth leads to a decrease in level of survival.
If not, then the effect may not be biologically relevant, however if there is a carry-over of effects into
the number of survivors, it can be considered biologically relevant’. That guidance document also
provides more information for dealing with dose–response relationships (see chapter 2.3.1 Determining
toxicity endpoints from avian and mammalian reproductive toxicity studies (EFSA, 2009c)).
3.1.5. About modelling approaches
In many risk assessments conducted by EFSA, modelling approaches related to biological relevance
are used:
• to predict the value of endpoints, relevant to the assessment question, which cannot be
measured at present time (e.g. spread of pathogens, see Annex A and Annex H);
• to estimate the value of biomarkers relevant to the assessed endpoints which cannot be
measured directly, for instance as done in the example of setting DRV in Vitamin D (Annex G);
• to estimate reference points for hazard characterisation in toxicological risk assessments by
BMD Modelling (EFSA, 2017)
• to assess large-scale or long-term effects on the biological system (Annex K);
Background variability of the control 
group according to prior knowledge 
Eﬀ
ect 
siz
e
 Control                                               Dose/concentraon 1                  Dose/concentraon 2              
Asterisks is dose/concentraon signiﬁcant diﬀerent from control group
Figure 3: An example showing an experiment where a statistically signiﬁcant treatment-related effect
falls within the background variability for the control group according to prior knowledge
and might be considered as irrelevant for risk assessment
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• to extrapolate the outcomes of the risk assessment to various populations/receiving
environments (Annex K);
• to assess the implications of uncertainties/assumptions on the outcomes of the risk
assessment, for example sensitivity analysis;
Such models are quantitative or qualitative. As far as they are based on sound approaches and
explicit assumptions, they can help risk assessors in understanding whether an effect size would be
biologically relevant in various contexts (populations/ecosystems) and help risk managers make
decisions. For further information on good modelling practice (see EFSA PPR Panel, 2014).
3.1.6. About biomarkers
Biological measurements are routinely carried out in studies on the interaction between an agent
and a biological system. A wide range of such measurements are called biomarkers. The nature of
these biomarkers is different and WHO identiﬁed three different classes of biomarkers: biomarker of
exposure, biomarker of effect and biomarker of susceptibility (WHO, 1993).
For chemical agents, a biomarker of exposure is deﬁned as ‘an exogenous substance or its
metabolite or the product of an interaction between a xenobiotic agent and some target molecule or
cell that is measured in a compartment within an organism’. Urine, blood, faeces or nails are common
media for the measurements of biomarkers of exposure.
A biomarker of effect is ‘a measurable biochemical, physiological, behavioural or other alteration
within an organism that, depending upon the magnitude, can be recognized as associated with an
established or possible health impairment or disease’. In relation to toxicity testing, it is important to
note that a biomarker of effect provides information for an effect, but does not necessarily
discriminate between adverse and non-adverse effects (Blaauboer et al., 2012). Its biological relevance
depends on its relation to MoA of an adverse effect or an adverse outcome pathway.
A biomarker of susceptibility is ‘an indicator of an inherent or acquired ability of an organism to
respond to the challenge of exposure to a speciﬁc xenobiotic substance’ (WHO, 1993).
A biomarker can also be associated with a reduction in resilience capacity, or health improvement
or improved resilience or maintenance of health of effect can be a single measure, but can also be a
standardised and deﬁned composite of different measures that together function as a biomarker of
effect.
3.2. Framework for consideration of ‘relevance’
In the framework presented below (Figure 4), biological relevance is considered at three main
stages related to the process of dealing with evidence:
• Development of the assessment strategy, in this context, speciﬁcation of agents, effects,
subjects and conditions.
• Collection and extraction of relevant data, i.e. identiﬁcation of biologically relevant
evidence/data as speciﬁed in the Assessment strategy.
• Appraisal and integration of the relevance of the agents, subjects, effects and conditions, i.e.
reviewing dimensions of biological relevance for each data set.
In the course of the assessment, it might become apparent that additional data would be of
relevance for the assessment and the process has to be reiterated.
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3.2.1. Development of the Assessment strategy and relation to biological
relevance
The assessment strategy should ensure that the assessment will answer the assessment question
(s). When developing the assessment strategy, the scope and objectives of the risk assessment should
be carefully considered, and if necessary, clariﬁed with the requestor. Further, if any questions arise in
the course of the assessment regarding the objective and scope of the assessment, they require
immediately to be addressed.
A number of relevance-related considerations should take place in the course of developing the
assessment strategy. One of the main considerations is to identify and specify biological relevant data,
before initiating the data collection. The following considerations depend on prior knowledge:
• Which is/are the agent(s) of interest for the assessment or activity assessed?
• What is/are the subject(s), population(s) that should be covered by the assessment, are
there any subgroups or sub-population particularly relevant that the assessment should
address more speciﬁcally? Are there some speciﬁc levels of protection (e.g. 95–99% of the
target population) to be considered? For environmental risk assessment, this issue is translated
into the concept of protection goal (see glossary and EFSA 2016b)?
• What is/are the effect(s) associated with the exposure to the agent(s) that is/are considered
as relevant for the assessment question?
Assessment strategy
- Specification of the agents
- Specification of the subjects
- Specification of the effects
- Specification of the conditions
Collection and extraction of data, 
i.e. identification of potentially 
biologically relevant evidence/data as 
specified in the Assessment strategy
Appraisal and integration of the 
relevance of:
- the agents
- the subjects 
- the effects
- the conditions
Figure 4: A framework of consideration of biological relevance at three main stages related to the
process of dealing with evidence
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• What are the relevant condition(s) regarding the exposure to the agent(s): route of
exposure, exposure duration, timing of exposure etc.?
In standardised assessments, i.e. assessments that strictly follow guidelines or guidance documents,
the assessment questions are generally already deﬁned in a standard form, and there is also a standard
procedure for assessing them. Sometimes also regulations prescribe what kinds of data are needed for
the assessment. The standardised questions and procedures are part of what Codex (2015) refers to as
‘risk assessment policy’, deﬁned as ‘Documented guidelines on the choice of options and associated
judgements for their application at appropriate decision points in the risk assessment such that the
scientiﬁc integrity of the process is maintained’. This deﬁnes what questions are relevant to a class of
assessments, and what effects, data and analysis are relevant for assessing them. It would also deﬁne
what kind of biological data and effects that are relevant. According to the Codex, (2015),3 for
standardised assessments, it is sufﬁcient to conﬁrm that the question deﬁned by risk assessment policy
is relevant to the case at hand. Where it is not, the assessor needs to interpret the terms of reference
and deﬁne relevant assessment questions in consultation with the decision-maker (Codex, 2015),3
which in effect establishes the assessment strategy speciﬁc to the case in hand. The assessor then has
to decide on what kind of biological data and effects would be relevant for the outcome of the
assessment.
In many areas of EFSA’s work where there are not standardised procedures, current practices for
conducting common types of assessments have developed, for which an assessment strategy may be
predetermined and documented, e.g. in guidance documents. This may imply that speciﬁc studies and
data as well as speciﬁc outcomes are considered relevant.
When using standardised procedures or current practices have developed, it is necessary to conﬁrm
that the procedure is relevant for the assessments at hand, but not necessary to reconsider the
relevance of every element of the procedure. Hence, it is essential to recognise that not all the
considerations of specifying biological relevant data have to be done de novo for every assessment.
In cases where a standard procedure is not fully relevant for answering the questions asked by the
requestor, the assessment becomes case-speciﬁc and the relevance of each element will need to be
considered. This is consistent with the concept of standardised and case-speciﬁc assessments in the
draft guidance on uncertainty (EFSA, 2016c).
3.2.2. Collection and selection of the biologically relevant data according to
speciﬁcations
The relevance-related considerations described in the previous section on the development of the
assessment strategy specify which evidence is relevant or irrelevant for the assessment and needed for
answering the assessment questions with the minimum possible uncertainty. The assessment strategy
should also serve as a basis for deﬁning the protocol/strategy for data collection.
Following the application of the protocol/strategy for data collection, all the data and information
collected should be evaluated for their relevance for the assessment (EFSA, 2017 WoE).
Data of low quality should not be a priori considered irrelevant and excluded, as they may contain
information important for the assessment. Instead, their implications should be considered, while
taking into account the limited quality and associated uncertainty. The criteria for inclusion/exclusion of
data should be explained and described within the risk assessment. If data are excluded, this should
be stated in the opinion along with the rationale for their exclusion.
It should be acknowledged that in the case of ‘standardised’ assessments, the relevance of some
evidence or data to be considered for the risk assessment is preset.
The legislation can also pre-determine the level of relevance of some of the evidence. This is the
case for example for the validation of health claims where human data are considered as relevant to
demonstrate and conclude on a positive effect, while other types of data (animal, in vitro or in silico)
are only considered as supportive evidence. For essential nutrients, conclusions may be based on
generally accepted knowledge. See also Annex G.
3 Codex (2015) states that the risk manager should establish risk assessment policy before risk assessment, in consultation with
the risk assessor and other interested parties. In current practice for EFSA assessments initiative for this tends to lie with the
assessor but, in principle, the decision-maker is responsible and should at least conﬁrm their agreement.
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3.2.3. Appraisal and integration of each data set collected
Reviewing dimensions of biological relevance for each data set
To review the relevance of a particular data set, the assessor should go back to the relevance-related
considerations to answer the assessment questions that have been identiﬁed during the problem
formulation phase and development of the assessment strategy (see Section 3.2.1):
a) Relevance of the agent
The assessor should consider whether the data set or the study under consideration provides
evidence directly on the agent subject to the assessment (e.g. nutrient, chemical substance,
microorganism, pathogen or invasive species).
Studies on similar (surrogate) agents that provide indirect evidence on the agent of interest might
have a certain amount of relevance to answer the assessment question; the fact that they do not
address the agent of interest itself should be considered a relevance-related uncertainty and further
characterised in term of impact on the assessment outcome (see Section 3.2.4).
For instance, when developing a farm-to-farm spread model in the case of the EFSA Scientiﬁc
report ‘Schmallenberg virus: State of the art’ (EFSA, 2014c) data on the related to Bluetongue virus
were used for certain parameters in case data on Schmallenberg virus were lacking.
For chemical agents, examples are the use of a structural analogue (QSARs or read-across), or a
metabolite, or a precursor, or a pure compound for a formulation).
A spectrum of strains is responsible for classical scrapie in sheep, and there may be variability in
properties that affect the ability to cross the human species barrier. In a study by Cassard et al. (2014),
mice models were used to evaluate the zoonotic potential of classical scrapie (See Annex C). Six different
isolates of classical scrapie were used. The BIOHAZ Panel concluded that the isolates used in the study
were relevant for the problem under investigation. However, evidence derived from a limited number of
classical isolates cannot be extrapolated to represent the whole biological variability of classical scrapie.
b) Relevance of the effect (nature and size)
For each effect, the ﬁrst step is to determine whether it is causally related to the exposure or
treatment (for instance according to the Bradford–Hill criteria that were developed for determining the
relationship between exposure and disease) (Hill, 1965).
In the context of causality between exposure and effect, some considerations could be:
• Is the effect dose related?
• Is there potential confounding? Is the effect a result of a confounding variable (an extraneous
variable that correlates with both the exposure and the effect)?
• Does the exposure precede the response according to a plausible time scale?
• Is the effect biologically plausible; is there any information on the Mode of Action?
The objective of the next step is to determine whether the observed effect, in its nature and size, is
relevant for the assessment question.
A wide range of assessment questions are considered by EFSA panels relating to many different
agents such as nutrient, chemicals, microorganisms, pathogens, invasive species or inserted gene
elements. Also, the target biological system (e.g. human, animals, ecosystems) assessed vary widely
between EFSA Panels. Hence, a large variability in the effects caused by the agent can be expected.
The scheme outlined below may be relevant to the assessment of chemical substances, but should
also be applicable to other agents.
Hence, as a ﬁrst step considering biological relevance, the assessor has to take into account the
nature of the effect caused by the agent (e.g. nutrient, substance, microorganism, pathogen or
invasive species) when addressing the assessment question. In this context, the assessor may need to
determine whether the effect in itself is adverse or beneﬁcial and, if not, whether it might be related
to such an outcome. Size or magnitude of the effect may be important and is the other dimension to
be considered when assessing the relevance of an effect.
A number of questions can help to decide on the (non-)relevance of the effect (see Figure 5):
1) Is the effect (in itself) an adverse or a beneﬁcial effect (see Section 3.1.1)?
• Is the nature of the effect such that it is clearly adverse according to the WHO deﬁnition or
beneﬁcial (see Section 3.1.1). For continuous data, this may also be a quantitative question
related to the size of the effect, which then have to be considered in a next step.
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• Does the effect represent an adaptive response (e.g. glycaemic regulation, body temperature
regulation)? If so, is it within the homeostatic capacity of the organism or system? For continuous
data, this may be a quantitative question related to the size of the effect (see also Section 3.1.1).
• Does the effect represent an adaptive response of a non-adverse nature? An example of such a
response is the caecum enlargement, which is commonly seen in rodents as a result of a ﬁbre
rich diet. Another example is the stimulation of the immune system following exposure to
microorganisms. One criterion to decide on a potential adverse effect is whether or not the
effect seen occurs in isolation, e.g. without pathological changes. (see also Section 3.1.1)?
• An example of a beneﬁcial effect is supporting defence against pathogens in the upper
respiratory tract, as measured by episodes of common cold and therefore biologically relevant
(see Annex G). The aim of the immune system is defence to pathogens, hence in case an
agent helps to support defence to pathogens, in this case measured by reduction of the
number of common cold episodes, the effect is considered beneﬁcial. EFSA only accepts such
effects when they are unequivocally demonstrated in the target species, i.e. the normal
population, and only if exposure precedes the effect. If the intention is to treat an already
existing disease, the agent, would be considered a drug, which is outside of the remit of
EFSA.
• Any effect of statistical signiﬁcance in the proper direction would be considered beneﬁcial. As
pathogens are risk factors for infections, reduction of the load of such pathogens may also
be considered as beneﬁcial; in any case it is essential to know the correlation between the
load of the pathogens and the infection that they may cause,
2) If the effect (in itself) is adverse or beneﬁcial, is the effect size of a sufﬁcient magnitude to be
considered relevant?
In scientiﬁc assessments, the critical effect size of adverse or beneﬁcial effects could be considered
as the effect size that would be of sufﬁcient magnitude to be biologically relevant. As discussed above
(see Section 3.1.4), the critical effect level is directly linked to the critical effects size and can be
deﬁned as the concentration or dose in the concentration/dose response relationship at which an
effect occurs or at which level the function of, e.g. an organ, system or a (sub)population, is changed.
In all cases, the background variability of the endpoint should be taken into account (see
Section 3.1.4).
One way of taking into account normal or background variability, or more generally the natural
variation of a biological system, is equivalence testing. A test of equivalence allows testing whether a
value is higher (or smaller) than a given threshold speciﬁed upfront, which can be derived from historical
control data gathered under comparable conditions, from estimation of the endpoint variability across
populations or ecosystems or from any critical effect size deemed biologically relevant.
By comparing values with the natural variation of the biological system not exposed to the agent
(i.e. responses to environmental or biological conditions other than the ones used in the assessment of
the agent), equivalence testing can help to assess their biologically relevance. While statistically
signiﬁcant differences may point at direct biological changes caused by an agent, they may not be
relevant from the safety viewpoint. By identifying those values outside normal, natural variation
equivalence testing may also help concluding on the safety relevance of the effects.
Equivalence testing is used in the safety assessment of genetically modiﬁed (GM) plants. In this
context, equivalence limits are not prespeciﬁed, but derived from plants varieties with an history of
safe use, grown and tested under the same environmental conditions as those used for control group
(see Annex GMO example for further details) (Annex F).
A critical effect size can be determined by using expert judgement (See EFSA, 2014a, Uncertainty
and WoE). This was for example used in the assessment of lead where a benchmark response (BMR)
of 1% for cognitive performance was chosen based on its distribution in the human population (EFSA,
2010). Another example is eggshell thinning and impact on egg cracking (Annex K) where the critical
effect level, the biologically relevant percentage of egg shell thinning, starts at 18% when egg shell
cracking begins to increase (EFSA, 2009c). In addition, models can be used for setting a critical effect
level. For example, models of focal species could be used to determine endpoints corresponding to
cut-off values set by speciﬁc protection goals (SPG). These models can be used for calculating critical
effect levels for certain types of effect, for instance for egg cracking, number of surviving chicks or the
size of litters, above which the population of the focal species will be negatively affected to such an
extent that the population will decline over time (see Annex K extended after public consultation to
include modelling).
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If a consensus on a critical effect size for the adverse effect is not reached by the experts involved
in the assessment, the EFSA SC recommends the use of default values. More speciﬁcally, a default
critical effect size or BMR of 10% (extra risk) should be used for quantal data and 5% (change in
mean response) for continuous data from animal studies. As stated in the guidance, the default BMR
may be modiﬁed based on statistical and biological considerations (e.g. when endpoint-speciﬁc
information is available). The rationale both for deviating from and using the default value should be
described and documented (EFSA, 2017).
For beneﬁcial effects, the same principles apply as for adverse effects to decide whether the
magnitude of the effect is biologically relevant. Very often, for beneﬁcial effects, only statistical criteria
are used; see for instance the example on health claims (Annex G). However, expert judgement using
a weight of evidence approach should be applied to judge the relevance of the beneﬁcial effects
observed, i.e. to decide on the magnitude to consider an effect as relevant. Cut-off values should
ideally be set a priori, but this is usually not done (see Annex F).
Another example is assessment of efﬁcacy of feed additives with the capacity to increase the
performance of chicken for fattening, providing positive economic effect for the farmer (see Annex E).
Any such effect exceeding the costs of the additive can be considered as potentially economically
relevant. The magnitude of the effect is also of importance. In this example, however, the animal itself
will not beneﬁt from this positive effect.
3) If the effect is not in itself adverse or beneﬁcial (e.g. a biochemical parameter), is it directly or
indirectly linked to a(n) adverse/beneﬁcial outcome?
In determining whether an effect is linked to an adverse/beneﬁcial outcome, it could be considered,
if the effect is a key event in the sequence of events leading to an adverse or beneﬁcial outcome (see
also Section 3.1.2). In this context, one of the questions resulting from the risk assessment of BPA
could serve as an example (see Annex D): ‘What is the biological relevance for human health of the
observed proliferative and morphological changes in the mammary gland following exposure to BPA
and the possible relevance for the development of breast cancer’? Ductal hyperplasia and an increase
of the number of terminal end buds may be regarded as supporting evidence for tumour formation
along with an increase in the proliferation of epithelial cells. However, these proliferative changes do
not need to be adverse by themselves, as epithelial cell proliferation is a normal physiological process
in certain life stages and per se does not lead to tumour formation and even may be reversible.
However, it is generally accepted that under certain pathological conditions such as recurrent tissue
damage and repair the proliferating tissue becomes more susceptible to tumour development.
Another well-known example is an alteration in circulating bioavailable thyroid hormone levels which
may have a serious impact on organs or organ systems other than the thyroid itself, such as on the
developing nervous system (see Annex I).
Some measured effects, such as liver enzyme induction, which may not be considered adverse in
themselves, can have a modulatory inﬂuence on e.g. the toxicity of other agents. This has to be
determined on a case-by-case basis.
An example of an indirect beneﬁcial effect would be the addition of the enzyme glucanase to the feed
of farm animals which has no signiﬁcant nutritional value itself but which facilitates the intestinal digestion
of cellulose, thereby enhancing the nutritional value of the feed (European Commission, 1996).
4) If the effect itself is directly or indirectly linked to a(n) adverse or beneﬁcial outcome, is the
effect size of a sufﬁcient magnitude to be considered relevant?
To assess this, similar considerations would apply as in point 2 above.
As an example, in the risk assessment of cadmium (see Annex J) b2-microglobulin (B2M) excretion in
urine was used as a biomarker for kidney damage. Renal toxicity is characterised by cadmium
accumulation in convoluted proximal tubules thereby causing cell dysfunction and damage, the earliest
sign of which is the decreased absorption of low molecular weight proteins from primary urine and
increased excretion of B2M. To determine the relevant size of the effect, prior knowledge on the
relationship between urinary excretion of B2M and renal function or damage was used. A level of 300 lg
B2M/g creatinine in urine was selected since exceeding this cut-off value has been associated with
accelerated decline of renal function and increased mortality. As high level criterion, a level above 1,000 lg
B2M/g creatinine was selected as exceeding this level would likely be associated with irreversible damage.
Another example is the use of biomarker to determine a population reference intake for vitamin D
(EFSA, 2016e). The complexity of vitamin D metabolism and the unknown contribution of its
endogenous synthesis do not allow determining a reliable vitamin D Average Requirement in the
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European population, hence calculating a Population Reference Intake for this population. The only
possible approach relies upon the use of a biomarker (of exposure) – calcidiol or 25(OH)D – of which
the serum concentration is related to bone health. Indeed, there is evidence of an increased risk of
adverse musculoskeletal health outcomes below a certain threshold (50 nmol/L). Meta-regression
analysis of the relationship between 25(OH)D serum concentration and total vitamin D intake allows to
set an Adequate Intake of 15 lg/day for the adult European population, an intake which should
ensure that most of the adult population will achieve a serum 25(OH)D concentration near or above
the target of 50 nmol/L. In this case, the relationships between the altered status of 25(OH)D and
adverse musculoskeletal health outcomes, on the one hand, and total vitamin D intake, on the other
hand, were considered as the biologically relevant parameters.
In the re-evaluation of food additive aspartame, the critical effects were identiﬁed as reproductive
effects in several animal species including humans (Annex B). The phenylalanine concentration in
plasma that is not associated with damage to the offspring, from which the level obtained from a meal
was subtracted, was used as a cut-off value. A bolus dose of aspartame to a normal subject reaching
this value was determined based on modelling. The current aspartame intake given the current ADI
was well below the dose required in PKU heterozygous individuals and it was concluded that there was
no safety concern.
The ﬁgure below describes a general decision tree to decide whether a biological effect is relevant
or not (Figure 5).
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c) Relevance of the subject
In many cases, proxies for the target species are used (e.g. rats instead of man, or standard
organisms to represent a group of organisms) to test the biological effects. The conclusion on whether
an effect is adverse/beneﬁcial or not, is speciﬁc to the test model under investigation.
No one to one extrapolation of the adverse or beneﬁcial effects observed in experimental settings
to humans/other species is generally possible. For example, if, following exposure to a chemical
substance, a tumour occurs in one test species only or in an organ (e.g. Harderian glands;
forestomach in rodents), which is not existing in humans, its relevance could be judged on the basis of
the MoA. If the MoA is not known, additional information needs to be taken into consideration.
An example of a positive effect that depends on an organ only presents in certain species is
utilisation of cobalt as precursor to vitamin B12 in rumen. The bacteria present in the rumen can
metabolise inorganic cobalt into vitamin B12. Mammals without a rumen, as in humans, are dependent
on the uptake of exogenous vitamin B12.
Effect under 
consideration
1. Is the effect in itself a(n) 
  adverse/beneficial effect?
2.Is the effect directly   
   or indirectly linked    
   to a(n) adverse/
   beneficial outcome?
Relevant
Is the size of the 
effect relevant for the 
assessment
Yes
No
No
No
Irrelevant
Yes
Yes
 
Figure 5: General decision tree to decide whether a biological effect is relevant or not
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In order to decide on the relevance of the test species to the human situation when testing
chemicals, it is important also to understand the qualitative and quantitative interspecies differences,
as well as the human variability in toxicokinetics (TK) and toxicodynamics (TD) processes. For a
particular agent, the level of knowledge on TK and TD processes can range from very basic (external
dose and toxicity) to a full quantitative understanding (external dose to internal dose to target organ
dose and metabolism (TK) to speciﬁc target organ toxicity (TD) (EFSA, 2014d).
In farm animals, (Annex E) beneﬁcial effects should be demonstrated in Efﬁcacy Studies performed
with the target animals. Extrapolations can be made for other categories of the target animals (e.g.
from chicken for fattening to hens for laying, or from piglets to pigs for fattening) or other species
(from dairy cows to other animals used for milk production, or from chicken to other avian species).
The relevance of information obtained from in vitro or in silico approaches needs to be considered
in conjunction with knowledge on the MoA and other available information.
In case of biological hazards; species speciﬁc pathogenicity will be considered to decide whether
the effect seen in the test species is relevant for the target species.
In a study by Cassard et al. (2014), mice models were used to evaluate the zoonotic potential of
classical scrapie (See Annex C). Transgenic mice over-expressing the human PrP gene and
homozygous and heterozygous for methionine and valine at codon 129 were inoculated intracerebrally.
The BIOHAZ Panel concluded that the mouse lines were well established and have been shown to be
susceptible to different CJD and BSE strains. Although overexpression of PrP is not a natural condition
in humans, and it might have impact on some biological parameters, this can be considered a
scientiﬁcally appropriate approach to modelling the molecular barrier for transmission of scrapie in
humans despite some limitations of these transmission models.
d) Relevance of the conditions
The conditions of the studies (environmental, toxicological, epidemiological, etc.) used for the
assessment should be looked at to decide on the degree of their relevance in relation to the
assessment question. Below experimental studies are used to illustrate these issues. They include:
Route of exposure
• It is evident that the exposure as applied in the toxicity test should be as close as possible to
the exposure route expected in the ﬁeld. This is not always feasible. For instance, in
environmental risk assessment for birds and mammals the assessment of the acute risk is
based on a gavage study (LD50). This test does not really mimic normal exposure in the ﬁeld
where bolus exposure rarely occurs. Animals exposed in nature are often exposed via
contaminated food over a period of time. In cases where the exposure is the result of an
exposure via diet or drinking water vs bolus exposure, the outcome may be different compared
with the bolus exposure (EFSA, 2005). The relevance of the exposure conditions should be
taken into account in the uncertainty analysis.
The route of exposure in a test system can sometimes be different from that in the target
system. An example of this is mice models that were used in a study to examine the zoonootic
potential of classical scrapie (See Annex C). The mice were inoculated intracerebrally. However,
natural exposure to the classical scrapie agent in man is believed to involve the oral route
through the consumption of meat from an infected animal. In this respect, the inoculation
route used in the mouse model does not represent an ideal strategy for the investigation of
zoonotic potential since the involvement of the digestive system, the rest of the
lymphoreticular system, the enteric nervous system and peripheral nervous system have been
bypassed by the direct deposition of the prions in the brain. Therefore, it was concluded that
the inoculation route used by Cassard et al. (2014) cannot reproduce ﬁeld conditions and does
not mimic natural exposure.
Timing of exposure
• For some compounds, the timing of exposure is crucial. The test should include the most
sensitive period of the animal’s life cycle. For instance, some pesticides do hamper/prevent the
moult of insects. When the duration of the test does not include a moulting event of the tested
species the effect of the compound will not be shown.
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Duration of exposure
• The duration of the test should mimic the duration of the exposure in the ﬁeld. In case the
duration in the ﬁeld is longer or shorter than the duration of the toxicity test or the toxicity in
the test did not reach a plateau (incipient toxicity), it is possible that the outcome of the
standard test does not provide the answer that is needed for the risk assessment.
Formulation or the vehicle used for exposure to the agent
• By assessing the toxicity of the agent, it should be assessed whether the other compounds/
additives added to the formulation do not inﬂuence the outcome of the toxicity test (this can
be in both directions: a less toxic outcome or a more toxic outcome). It is also worthwhile to
assess the vehicle used to apply the toxic compound to the test organism or the test system
(often the vehicle is tested on its own).
Field studies (environmental and epidemiological studies)
• For ﬁeld studies, additional criteria have to be checked, for instance, whether the important
animal groups are represented in the ﬁeld study. These types of criteria will not be discussed
in this document, but are important issues to be considered when judging whether the
outcome of a test can be used in risk assessment (see for instance, the guidance document for
aquatic organisms (EFSA, 2013a,b)
Other parameters, such as the number of animals per dose groups, number of doses tested, etc.
are more related to reliability of the evidence (EFSA, 2017).
3.2.4. Uncertainty related to the relevance
Including evidence with less biological relevance adds to the overall uncertainty. Uncertainties
arising when assessing biological relevance should be addressed and described together with other
uncertainties at all stages of the assessment, including data gaps. General guidance on methods for
assessing sources of uncertainty and their impact on assessment conclusions are provided by EFSA,
(2016c), and can be applied to uncertainty arising from considering evidence that have limitations in
their relevance as well as from other sources.
4. Reporting the assessment of biological relevance
Assessing biological relevance should be addressed and described as part of the weight of evidence
assessment. General guidance on methods for reporting weight of evidence assessment conclusions is
provided by EFSA, 2017, and can be applied to the assessment of biological relevance.
If the assessment of the biological relevance has been conducted following a standardised
procedure previously established for use in this area of EFSA’s work, the assessment of the biological
relevance may be reported in the manner that is normal for that standardised procedure, provided this
is transparent. The standardised procedure should be referenced and its applicability to the case in
hand should be explained if it is not self-evident.
All other assessments of the biological relevance should be reported following the proposed
framework according to the three basic steps of assessment of the biological relevance: (1)
Development of the assessment strategy, including speciﬁcation of agents, effects, subjects and
conditions; (2) Collection and extraction of data, i.e. identiﬁcation of potentially biologically relevant
evidence/data as speciﬁed in the assessment strategy; (3) Appraisal and integration of the relevance
of the agents, subjects, effects and conditions, i.e. reviewing dimensions of biological relevance for
each data set. This reporting should be included in the report of the weight of evidence assessment.
Reporting should be consistent with EFSA’s general principles regarding transparency (EFSA, 2006,
2009a) and reporting (EFSA, 2014a, 2015a,b). The assessment of the biological relevance should
include justifying the choice of methods used, documenting all steps of the procedure in sufﬁcient
detail for them to be repeated, and making clear where and how expert judgement has been used.
Where the assessment used methods that are already described in other documents, it is sufﬁcient to
refer to those. Reporting should also include referencing and, if appropriate, listing or summarising all
evidence considered, identifying any evidence that was excluded; detailed reporting of the conclusions;
and sufﬁcient information on intermediate results for readers to understand how the conclusions were
reached.
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Guidance on reporting other parts of the wider procedure, including evidence review, problem
formulation and uncertainty analysis, is provided elsewhere (e.g. EFSA, 2014b, 2015a, 2016c).
5. Conclusions and recommendations
• This guidance document is intended to guide EFSA panels and staff in the assessment of the
biological relevance of scientiﬁc evidence. When addressing the mandate, the SC
acknowledged that the issue of biological relevance in risk assessment has a broader meaning
than the biological relevance of an effect as described in the Terms of Reference. In fact, it
encompasses also aspects related to the deﬁnition of the problem formulation. This, in turn,
guides the development of the assessment strategy, which includes the decision on which data
to use for the assessment (relevance of the data).
• Relevance is a fundamental concept in dealing with evidence and has different implications in
terms of elements to be considered at different stages of the assessment and it can only be
determined when the assessment question is well deﬁned, which forms the basis for
developing an assessment strategy.
• A framework was developed in which biological relevance is considered at three main stages
related to the process of dealing with evidence:
 Development of the assessment strategy, in this context, speciﬁcation of agents, effects,
subjects and conditions in relation to the assessment question(s).
 Collection and extraction of data, i.e. identiﬁcation of potentially biologically relevant
evidence/data as speciﬁed in the Assessment strategy.
 Appraisal and integration of the relevance of the agents, subjects, effects and conditions,
i.e. reviewing dimensions of biological relevance for each data set.
 the agent; it should be considered whether the assessment is based on the agent of
concern or on a surrogate agent (e.g. substance or biological agent behaving
similarly to agent of concern).
 the subject; it should be considered whether the assessment is based on the
subjects of concern, (e.g. for human studies in humans) or in case proxies (e.g.
animal models for humans) are used the relevance of effects occurring in these for
the subject of concern should be considered.
 the effect; a wide variety of effects may be considered. Consideration should be given
as to whether the effect is causally related to exposure to the agent, and the nature
of the effect should also be taken into account, i.a. homeostatic response, adaptive,
adverse/beneﬁcial or directly or indirectly linked to an adverse/beneﬁcial effect.
Finally, for effects where the size of the effect is critical, it should be assessed whether
the magnitude of the effect is sufﬁcient to be of biological relevance (e.g. outside
normal variation, for effects directly or indirectly linked to an adverse/beneﬁcial effect
whether they are of sufﬁcient magnitude to result in an adverse/beneﬁcial outcome)
and thereby of importance for the assessment outcome as both positive and negative
ﬁndings may inﬂuence the answer to the assessment question. It should be noted
that the biological relevance of an effect can vary according to the assessment
question.
 the conditions; it should be considered whether the conditions of the studies
(environmental, toxicological, epidemiological, etc.) used for the assessment are
relevant for the conditions under consideration.
 It is acknowledged that in speciﬁc subject areas EFSA Panels conduct standardised
assessments that strictly follow guidelines where assessment questions, biological
relevance of effects and biological systems may be predeﬁned.
• Each step of relevance considerations may be source of uncertainty. The assessor should
address these uncertainties as a part of the general uncertainty analysis of the assessment.
The SC Guidance on Uncertainty (EFSA, 2016c) should be followed.
• The EFSA SC acknowledges that the diversity of ﬁelds covered by the different EFSA Panels
impacts how the guidance could be implemented. Depending on different types of agent (e.g.
nutrient, chemical substance, microorganism, pathogen or invasive species), target subjects and
different types of outcomes dealt with in the assessments, EFSA Panels may in the course of
implementation identify needs for guidance documents to be developed in more speciﬁc areas.
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• It is suggested that EFSA collaborate at the European and international level with relevant
organisations and initiatives to harmonise developments in this area.
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Examples of biological relevance considerations in panel-speciﬁc scientiﬁc
assessments
Annex A – AHAW
Case study of biological relevance in the area of animal health – Risk of
introduction and establishment of Rift Valley Fever in the countries
neighbouring the EU
Assessment strategy
Rift Valley Fever (RVF) virus is a vector-borne virus that affects ruminants. Humans can contract
the infection when in close contact with infected ruminants. The causative agent is a Bunyavirus that is
endemically present in Sub-Saharan Africa. The European Commission wanted to know whether the
virus is moving its territory in Northern direction.
Agent Effect Subject Condition
Rift Valley
Fever virus
Introduction into
Mediterranean countries
neighbouring the EU
Ruminant
Population
Prevalence of the infection in Sub-Saharan Africa
Movement of ruminants into region of concern
Movement of vectors into region of concern
Humans
Agent Effect Subject Condition
RVF virus Establishment Ruminant
Population Infection dynamics model
Geographical density of ruminants
Temperature in the geographical regions
Geographical density of competent vectors
(literature and further extrapolated based on
suitability of the habitats)
Temperature in the geographical regions
Problem formulation: What is the risk of entry and establishment of RVF into the Mediterranean
countries neighbouring the EU.
Evidence/data needed to address the question
Risk of Entry: Quantitative assessment of probability of introduction
• Prevalence of the infection in source countries in Sub-Saharan Africa (data originated from
literature review and OIE outbreak information; in general data availability was limited and
available data was fragmented).
• Data of movement of animals from source countries to region of concern (this is
undocumented trade, so no data available; estimates were made using formal expert elicitation
(Shefﬁeld method)).
• Data on movements of competent vectors from source countries to region of concern (data
were derived from literature and expert elicitation).
Risk of Establishment: Modelling infection dynamics with regard to presence and density of
ruminants and competent vectors.
• Infection dynamics model (a model described in literature was used).
• Identifying competent vectors (these were derived from literature).
• Geographical density of competent vectors (derived for a small part from literature, further
extrapolated based on suitability of the habitats).
• Geographical density of ruminants (data derived from FAO).
• Temperature in the geographical regions (based on temperature records of the region).
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Data evaluation
Relevance of the agent
Rift Valley Fever virus is a zoonotic virus of the family Bunyaviridae that has ruminant species as
reservoir hosts. Infected animals suffer from fever, young animals may die and pregnant animals may
abort. The infection is primarily transmitted between animals through mosquitos. Humans can contract
the infection when in close contact to animals. Most infected humans follow a subclinical or mild (fever,
headache, muscle pain) course, but a small percentage of patients develops severe disease.
Relevance of the subject
For the AHAW Panel, ruminants were the relevant subjects. These species are the reservoir hosts of
the virus. There is no evidence for sustainable human to human transmission.
Relevance of the effect
Two effects were examined: (1) Risk of introduction into the Mediterranean countries neighbouring
the EU and (2) Risk of establishment in those countries. Both are directly related to the question asked
by the requestor.
Relevance of the conditions
For both the risk of introduction and the risk of establishment, a mathematical model was used to
assess the risk. This is a generally accepted assessment, because it is not possible to study these
questions empirically. The introduction question included the possible routes of infection, the contact
rate, prevalence of the infection in the source countries and likelihood of virus survival during the
transport. Upon introduction, the infection may either fade out quickly after infecting only one or a few
animals, or result in extensive transmission, which is primarily dependent on the densities of ruminants
and that of competent vectors. Whether as a consequence of this spread the virus will become
endemic is dependent of the host population size (in a relatively small population the inﬂux of new
susceptible animals might be insufﬁcient for maintenance of infection) and climate (if temperatures
drop in the winter to values that do not enable the vector cycle, infection will fade out in winter).
Overall conclusion
The assessment revealed that the introduction of RVF in the region of concern is highly likely, but
most often takes place in regions where the combined ruminant and vector density is insufﬁcient to
result in establishment. However, according to the assessment, the region of concern has regions
where RVF could become endemic.
Uncertainty
The main potential sources of uncertainties in this setting may be summarised as follows:
• mathematical models are a simpliﬁcation of reality;
• uncertainty around model parameters in particular:
 movement of animals from Sub Saharan to Northern Africa was derived using expert
elicitation;
 vector density was mostly based on the presence of suitable vector habitat only; uncertainty regarding vector competence of vectors present in Northern Africa.
The uncertainty around the number of introductions was high (but also the lower limit of the
estimate indicates a likely introduction). Due to sparse data, the uncertainty around the vector
densities is also high and it is uncertain how the competence of vectors can vary within a certain
vector species.
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Case study of biological relevance in the area of animal welfare – Gas
stunning and unconsciousness at slaughter
Assessment strategy
In the slaughter process, animals are killed by exsanguination. However, in order to avoid pain and
suffering, they should be rendered unconscious prior to exsanguination and remain so until death
occurs through loss of blood. In most cases, poultry are stunned using an electric current, but recently
gas stunning has gained interest due to animal welfare advantages. It is to be expected that the
industry will continue to develop new stunning methods or modify electrical or gas stunning
parameters. It is therefore important to ensure that the new or modiﬁed stunning methods meet
animal welfare standards. Thus, an assessment protocol has been developed to evaluate new or
modiﬁed stunning methods.
Agent Effect Subject Condition
Stunning method Loss of consciousness Poultry Slaughter
Problem formulation: To maintain good standards of animal welfare, it is important to establish
whether the new or modiﬁed stunning method (a) produces immediate loss of consciousness, (b) if
loss of consciousness is not immediate, does it cause avoidable pain and suffering during the induction
of unconsciousness, and (c) is the duration of unconsciousness long enough to avoid recovery of
consciousness either prior to slaughter or during exsanguination.
Evidence/data needed to address the question
First, the brain mechanism associated with the induction of unconsciousness by a new or modiﬁed
stunning method needs to be clearly explained. The state of consciousness can be ascertained under
the controlled laboratory conditions by recording spontaneous as well as evoked activity in the brain
using electroencephalograms (EEGs) before and after the application of a stunning method. The
unique brain states that are incompatible with persistence of consciousness should be demonstrated
using EEGs. Secondly, the correlation between EEG evidence and animal based indicators (as proxies)
of unconsciousness for monitoring in slaughterhouses also need to be established. Thirdly, the duration
of unconsciousness should be determined. In essence, the duration of unconsciousness should be
longer than the sum time interval between the end of stunning and cutting blood vessels in the neck
and the time it takes for the onset of death through exsanguination. Finally, the maximum permissible
time between the end of stunning and neck cutting should be established.
Data evaluation
Relevance of the agent
Killing animals by exsanguination is a potentially painful process and the sources of pain includes,
(a) cutting soft tissues, nerves and blood vessels in the neck (sawing motion or making several cuts),
(b) direct activation of neurones by the blade as it transects the nerves produce intense pain and (c)
the sensations produced during the injury discharge is likely to be an amalgam of all such inputs, and
the overall effect is likely to be a sense of shock, comparable to an electric shock.
Relevance of the subject
Poultry is the relevant subject for the question, because it is also the target species for slaughter.
Relevance of the effect
The pain and suffering at exsanguination can be prevented by implementing pre-slaughter stunning
of animals, i.e. rendering them unconscious prior to exsanguination.
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Relevance of the conditions
The tests are done with the target species in a slaughterhouse setting. In this context, the brain of
an animal is considered to be the seat of consciousness
Overall conclusion
Useful to test stunning methods according to the guideline.
Uncertainty
Establishing neuronal correlates of unconsciousness remains to be a challenge. For example, the
magnitude of changes occurring in the EEG considered to be incompatible with persistence of
consciousness varies widely. The correlation between EEG criteria and animal based indicators of
unconsciousness is not widely reported, and hence, rely on expert opinion.
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Annex B – ANS
Re-evaluation of aspartame (E 951) as a food additive
Introduction
Following a request from the European Commission, the Panel on Food Additives and Nutrient
Sources added to Food (ANS) of the European Food Safety Authority (EFSA) was asked to deliver a
scientiﬁc opinion on the re-evaluation of aspartame (E 951) as a food additive.
Aspartame (E 951) is a dipeptide of L-phenylalanine methyl ester and L-aspartic acid bearing an
amino group at the a-position from the carbon of the peptide bond (a-aspartame). The major
hydrolysis and degradation products of aspartame are L-phenylalanine, aspartic acid, methanol and
5-benzyl-3,6-dioxo-2-piperazine acetic acid (DKP).
For the purpose of the guidance and although the scientiﬁc assessment of Aspartame had a
broader content, the example below focuses only on one effect.
Agent Effects Subjects Conditions
Aspartame Developmental
effects
Rats and rabbits Reproductive and developmental studies
Humans heterozygous or homozygous
for phenylalanine hydroxylase (PAH)L-phenylalanine
Methanol
Aspartic acid
Phenylketonuria
(PKU) patients
Assessment strategy
The re-evaluation of aspartame included the assessment of the safety of its gut hydrolysis
metabolites methanol (which is oxidised to formaldehyde), phenylalanine and aspartic acid. The
hepatic enzyme phenylalanine hydroxylase (PAH) is necessary to metabolise the amino acid
phenylalanine to the amino acid tyrosine. When PAH activity is reduced, circulating phenylalanine levels
will increase. Humans heterozygous for PAH mutations, show a slightly reduced capacity to metabolise
phenylalanine compared to normal individuals. Individuals homozygous for PAH mutations,
phenylketonuria (PKU) patients, have a markedly reduced capacity for phenylalanine metabolism.
There is long established evidence for increased severity and frequency of adverse developmental
effects with high phenylalanine plasma levels in human patients with PKU. Maternal PKU syndrome
refers to the teratogenic effects of PKU during pregnancy. In untreated pregnancies wherein the
mother has classic PKU with a plasma, phenylalanine level greater than or equivalent to 1,200 lM
(20 mg/dL), abnormalities in offspring occur at high frequencies.
The pathogenesis of this syndrome is unknown; it may be related to inhibition by phenylalanine of
neutral amino acid transport across the placenta or to direct toxicity of phenylalanine and/or a
phenylalanine metabolite (phenylpyruvic acid) in certain fetal organs.
Speciﬁcation of the agent
Hydrolysis of aspartame in the gastrointestinal tract is essentially complete and there is no systemic
exposure to aspartame but systemic exposure to aspartic acid, phenylalanine and methanol do occur.
Speciﬁcation of the subject(s)
Adverse developmental effects have been reported in rats and rabbits treated with aspartame as
well as with phenylalanine. Due to the very efﬁcient hydrolysis in the gastrointestinal tract, the amount
of intact aspartame that enters the bloodstream has been reported to be undetectable in several
studies conducted in rats, dogs, monkeys and humans. Based on the sensitivity of the detection of
radioactivity following labelling of the phenylalanine, aspartate and methyl moieties of aspartame, it can
be concluded that aspartame is completely hydrolysed in the gut to yield aspartate, phenylalanine and
methanol. These metabolites are then absorbed and enter normal endogenous metabolic pathways. An
limit of detection (LOD) is not given for aspartame. The LOD for methanol is 3.5–4 mg/L.
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Speciﬁcation of the effect(s)
After birth, homozygous PKU babies show severe impairment in development and cognition if the
phenylalanine intake via the diet is not strictly controlled. Adverse developmental effects were seen in
children born to PKU patients and that these effects appeared to be related to maternal phenylalanine
levels. It has been reported that the effects of phenylalanine in PKU mothers and their children both
before and after birth had developed considerably since the initial evaluation of aspartame.
The MoA proposed for aspartame was that the toxicological effects observed in rats and rabbits
during pregnancy were due to the metabolite phenylalanine. It has been postulated that phenylalanine
could be responsible for some or all of the adverse effects reported for aspartame in developmental
toxicity studies with rats and rabbits.
Data collection
The evaluation is based on original study reports and information submitted following public calls
for data, previous evaluations, and additional literature that became available until the 15 November
2013.
A complete package of embryotoxicity, reproductive and developmental toxicity studies on
aspartame in rats, mice and rabbits have been performed. Some of these studies were also conducted
with the aspartame metabolite phenylalanine.
Appraisal and integration of the evidence
Relevance of the agent(s) and the subject(s)
The results of the reproductive and developmental toxicity studies in rats indicated NOAELs that
ranged from 2,000 to 4,000 mg aspartame/kg body weight (bw) per day. Developmental changes in
pup weight were observed at birth in studies at the dose of 4,000 mg aspartame/kg bw per day,
which could be attributed to a combination of malnutrition and nutritional imbalance due to excessive
exposure to phenylalanine derived from aspartame. This hypothesis was supported by the observation
that administration of a dose of phenylalanine equimolar to aspartame led to a similar decrease in
maternal and pup weight of rats, as observed in a concurrent aspartame group.
The data from the reproductive and developmental toxicity studies performed with rabbits were
confounded both by the decrease in feed intake or the poor health of the animals, and, in many cases,
by the number of deaths of pregnant rabbits in the treated groups possibly related to misdosing during
gavage treatment.
Relevance of the effect(s)
The key effects observed in the reproductive studies with rats and rabbits related to a speciﬁc life
stage acknowledged to be critical in both species and to humans. A spectrum of effects was observed
in the rats and rabbits, particularly maternal toxicity and growth restriction of the offspring. The latter
effect was recognised as an important outcome in humans because it was associated with an
increased risk of perinatal mortality and morbidity. Developmental changes in pup body weight were
observed at birth in studies at a dose of 4,000 mg aspartame/kg bw per day and considered to be
attributed due to the excessive exposure to phenylalanine derived from aspartame. This was
supported by the observation that administration of a dose of L-phenylalanine equimolar to aspartame
led to a similar decrease in maternal and pup weight, as observed in a concurrent aspartame group.
Relevance of the conditions
The available reproductive and developmental toxicity studies on aspartame comprised nine
studies, one in mice and eight in rats. In addition, eight embryotoxicity and teratogenicity studies were
performed in rabbits, four with administration of aspartame by diet and four by gavage.
The best estimate of the critical effect level of phenylalanine exposure without damage to the
offspring is 330–360 lM. In calculating a safe level of aspartame exposure (based on plasma
phenylalanine concentrations), the worst-case scenario was applied, that took into account that intake
of aspartame occurs in combination with a meal leading to circulating plasma phenylalanine
concentrations of 120 lM.
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The concentration of plasma phenylalanine derived from aspartame was, therefore, set to 240 lM
(i.e. 360 – 120 lM).
Based on modelling, a plasma phenylalanine concentration of 240 lM would result from the
administration of a bolus dose of 103 mg apartame/kg bw to a normal subject.
For a PKU heterozygous individual, the concentration of 240 lM would be reached by the
administration of a bolus dose of 59 mg aspartame/kg bw.
Uncertainties
The following main assumptions were made based on the proposed MoA:
• Phenylalanine plasma level of 360 lM is the threshold for developmental effects.
• The diet results in phenylalanine plasma level not exceeding 120 lM.
• Peak plasma phenylalanine concentration can be used in the dose–response modelling as
surrogate of steady-state plasma phenylalanine concentration.
• Bolus administration of aspartame can be used in the dose–concentration modelling of plasma
phenylalanine to represent a more typical pattern of aspartame intake.
• The 95th percentile conﬁdence interval of the lower bound estimate of the aspartame
dose–plasma phenylalanine concentration curve provides a safe limit for plasma phenylalanine
for the entire population (with the exception of homozygous PKU patients).
• The increase in plasma phenylalanine concentrations following aspartame administration will be
the same in the general population as in individuals heterozygous for PKU.
• Reproductive and developmental toxicity of aspartame is solely dependent on systemic
exposure to phenylalanine.
• There is no requirement for a pharmacodynamic uncertainty factor (a sensitive human
population (PKU patients) was used to deﬁne the threshold).
• There is no requirement for a pharmacokinetic uncertainty factor (the aspartame plasma
phenylalanine concentration was based on a more sensitive human subpopulation (PKU
heterozygous)).
It was not possible to place a speciﬁc numerical value on the uncertainties related to these
assumptions, but the aforementioned evaluations and considerations are more likely to overestimate
than underestimate any potential developmental risk. Therefore, it is not illogical to conclude that the
results of the uncertainty analysis further support the conclusion, that there is no safety concern for
aspartame at the current ADI in normal and heterozygous subjects.
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Annex C – BIOHAZ
Case study of biological relevance in the area of biological hazards -
Zoonotic potential of classical scrapie
Introduction
Transmissible spongiform encephalopathies (TSEs) are a group of progressive conditions that affect
the brain and nervous system of many animals, including humans. Unlike other kinds of infectious
disease, the infectious agent in TSEs is believed to be a protein, called the prion protein. Misshapen
prion proteins are transmissible and are able to induce abnormal folding of speciﬁc normal cellular
proteins that are found most abundantly in the brain: they carry the disease between individuals and
cause deterioration of the brain. TSEs are unique diseases in that their aetiology may be genetic,
sporadic or infectious via ingestion of infected materials and via iatrogenic means (e.g. blood
transfusion). Prion diseases of humans include sporadic Creutzfeldt–Jakob disease (sCJD), new variant
Creutzfeldt–Jakob disease (vCJD), Gerstmann–Straussler–Scheinker syndrome, fatal familial insomnia
and kuru. Prion diseases of livestock include bovine spongiform encephalopathy (BSE) in cattle,
classical scrapie in sheep and chronic wasting disease in cervids.
Host genetics substantially inﬂuence these diseases. In humans, familial prion diseases are closely
associated with mutations in the prion protein gene, and the methionine/valine polymorphism at codon
129 appears to inﬂuence susceptibility, incubation period and in some respects disease phenotype.
One of the main questions in relation to the animal TSEs is their ability to infect humans. BSE is the
only TSE agent identiﬁed as zoonotic. However, it has been hypothesised that other prions associated
with animals such as classical scrapie can infect humans. For disease to develop in the case of
exposure through foodstuffs, there must be exposure to a sufﬁcient dose of the agent, the agent must
be taken up from the gastrointestinal tract, enter the nervous system and be successfully transported
to the neuronal cell bodies in the central nervous system. The infecting agent must then be able to
‘convert’ the cellular prion protein (PrPC) to the abnormal from of the prion protein (PrPSc) at a rate
which enables accumulation of sufﬁcient PrPSc to cause disease within the life-span of the host.
Assessment strategy
In a paper, ‘Evidence for zoonotic potential of ovine scrapie prions’, published in Nature, Cassard
et al. (2014) studied the zoonotic potential of classical scrapie by bioassay in mice, in which a range of
characteristics were assessed. These included incubation periods and neuropathological characteristics.
The authors concluded that the results demonstrated that scrapie prions have zoonotic potential and
raise new questions about the possible link between human and animal prions. The European
Commission asked the BIOHAZ Panel to scientiﬁcally appraise the paper considering the limitations,
assumptions and uncertainties associated with the study design and outputs.
In line with the framework set out in Figure 1 of the main document for consideration of relevance,
the agent, effect, subject and conditions can be considered as follows:
Agents/exposure Effect/outcome Subject/population Conditions
Classical scrapie agent TSE Human Oral exposure through the consumption
of meat from an infected animal
Hence, the problem can be formulated in these terms: in humans, can the consumption of meat
from classical scrapie infected sheep result in the development of a TSE?
Evidence/data needed to address the question
The evidence for the zoonootic potential of classical scrapie, as set out in the paper by Cassard
et al. (2014), was evaluated by the BIOHAZ Panel using expert judgement.
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Appraisal and integration of the evidence
Relevance of the agent
A spectrum of strains is responsible for classical scrapie in sheep, and there may be variability in
properties that affect the ability to cross the species barrier. There is experimental evidence that some
isolates may not be completely stable, and their fundamental properties may shift on transmission.
There is also potential heterogeneity of geographical distribution of individual strains.
In the study by Cassard et al. (2014), six different isolates of classical scrapie were used. These
had been previously studied in other animal models and showed some degree of biological variability.
The BIOHAZ Panel concluded that the deliberate selection of biologically variable scrapie isolates
represents an important new aspect compared to previous studies on the subject, given the known
diversity within the group of TSE agents identiﬁed as classical scrapie. The Panel further concluded
that no case selection will conclusively and comprehensively ever represent the total potential ﬁeld
exposure, but the Cassard et al. (2014) study made a good, rational and supported choice of isolates
designed to be distinct from one another, to represent some of the possible range of ﬁeld strains.
In conclusion, the isolates used in the study by Cassard et al. (2014) were considered relevant for
the problem under investigation. However, evidence derived from a limited number of classical isolates
cannot be extrapolated to represent the whole biological variability of classical scrapie.
Relevance of the subject
In the study by Cassard et al. (2014), animal models were used to evaluate the zoonotic potential
of classical scrapie. Transgenic mice overexpressing the human PrP gene and homozygous and
heterozyous for methionine and valine at codon 129 were inoculated intracerebrally. Historically,
laboratory studies using animal models were carried out using wild-type mice. However, a substantial
proportion of human and animal TSE isolates cannot be propagated into conventional mice models,
which limits the usefulness of this system to characterise and compare TSE agents circulating in the
ﬁeld. More recently, transgenic mice with PrP derived from different species have been increasingly
used in experimental transmission of TSE agents. Transgenic mice that are homozygous for methionine
at codon 129 of the human PrP gene have been previously shown to be fully susceptible to human
TSEs, such as sCJD and vCJD and, to a much lesser extent, cattle BSE, the only animal TSE with
conﬁrmed zoonotic potential identiﬁed so far.
Different lines of transgenic mice that express the human PrP gene were used in the study, namely
the tg340, tg361 and tg650 mouse lines. The tg340 mouse line expresses methionine approximately
fourfold more than normal human brain tissue at codon 129. The tg650 mouse line overexpresses
methionine sixfold at the same codon. The tg361 mouse line overexpresses valine at codon129 at
fourfold levels. A breeding cross between the tg340 and the tg361 provided mice that overexpress
both M129 and V129 alleles at similar levels. Although PrP overexpression might circumvent the low
susceptibility of gene-targeted tg mice, it is worth noting that an inevitable limitation of such
transgenic mice is that only one human gene is present in the model, while disease susceptibility and
incubation period are inevitably multifactorial. Additionally, if the time taken for the conversion of
human PrPc to PrPSc exceeds the lifespan of the mouse, this may give a ‘false negative’ outcome.
The BIOHAZ Panel concluded that the mouse lines used by Cassard et al. (2014), in particular
tg650 and tg340, are well established and have been shown to be susceptible to different CJD and
BSE strains. Although overexpression of PrP is not a natural condition in humans, and it might have
impact on some biological parameters, this can be considered a scientiﬁcally appropriate approach to
modelling the molecular barrier for transmission of scrapie in humans despite some limitations of these
transmission models, as mentioned above.
Relevance of the effect
In the study, serial passages were used in the transgenic mice for each of the six different strains
of classical scrapie. Serial passages of bovine BSE, human sCJD isolates and human vCJD isolates were
also carried out in these mouse lines for comparison with the classical scrapie isolates. Based on the
attack rates observed after serial passages in transgenic mice, the potential for classical scrapie
transmission is: (i) low or absent in MM129 mice; (ii) low or absent in MV129 mice; (iii) absent in
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VV129 mice. The data suggest that BSE is still more efﬁcient than scrapie in MM129 mice, while a
single scrapie isolate would be more efﬁcient than BSE in MV129 mice
Moreover, the study also showed that the serial transmission of different scrapie isolates in
humanised transgenic mice led to the propagation of prions that were phenotypically identical to those
that cause sCJD in humans.
In summary, the effect shown by Cassard et al. (2014) was considered relevant. The study showed
that transgenic mice could be infected with classical scrapie strains but that the transmission was less
efﬁcient than for bovine BSE. It should also be noted that while serial passage maximises the chance
of detecting the propagation of TSE agents, it does not mimic natural exposure in humans.
Relevance of the conditions
Intracerebral inoculation is a widely accepted and appropriate choice of inoculation in mouse
models. This method can be used to assess the permeability of the transmission barrier at the
molecular level, i.e. the conformational compatibility between the infecting prion strain and the PrPc of
the recipient species. This is an important factor which limits the propagation of prion agents among
different species. Successful ampliﬁcation of PrPSc would indicate that the TSE strain has the potential
to convert human PrPc.
Natural exposure in man is believed to involve the oral route through the consumption of meat
from an infected animal. In this respect, the inoculation route used in the mouse model does not
represent an ideal strategy for the investigation of zoonotic potential since the involvement of the
digestive system, the rest of the lymphoreticular system, the enteric nervous system and peripheral
nervous system have been bypassed by the direct deposition of the prions in the brain.
Therefore, it was concluded that the inoculation route used by Cassard et al. (2014) cannot
reproduce ﬁeld conditions and does not mimic natural exposure.
Overall conclusion
The BIOHAZ Panel concluded that the paper by Cassard et al. (2014), provides evidence that some
classical scrapie isolates can propagate in humanised transgenic mice and produce prions that on
second passage are similar to those causing one form of sCJD. However, the BIOHAZ Panel also
concluded that the results from the study raise the possibility that scrapie prions have the potential to
be zoonotic but do not provide evidence that transmission can or does take place under ﬁeld
conditions.
Uncertainty
The main potential sources of uncertainties in this experimental setting may be summarised as
follows:
• Evidence derived from a limited number of classical isolates cannot be extrapolated to
represent the whole biological variability of classical scrapie.
• The use of an animal model and the over-expression of PrP may not allow a direct
extrapolation to human population.
• Subsequent serial passages were thought as a way to overcome the problem of allowing a
longer incubation period in mice: the occurrence of a similar condition is not realistic in the
ﬁeld.
• The intracerebral inoculation route used by Cassard et al. (2014) cannot reproduce ﬁeld
conditions and does not mimic natural exposure.
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Annex D – CEF
Evaluation of the toxicity of BPA for humans considering all relevant
toxicological information
Assessment strategy
The EFSA scientiﬁc Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
(CEF) has re-assessed in 2015 the risks to public health from BPA exposure by evaluating the toxicity
of BPA for humans, including for speciﬁc (vulnerable) groups of the population (e.g. pregnant women,
infants and children, etc.) and considering all relevant toxicological information available. Exposure
assessment was performed for various groups in the population and ﬁnally human health risks were
characterised taking into account speciﬁc groups of the population [EFSA Journal 2015; 13(1): 3978].
Although the scientiﬁc assessment of BPA had a broader content, for the purpose of this guidance
the example below focuses only on one effect.
Speciﬁcation of the agent
Bisphenol A (BPA) is an organic chemical used as a monomer in the manufacture of polycarbonate
plastics and epoxy resins and as an additive in plastics. Polycarbonates are used in food contact
materials such as reusable beverage bottles, infant feeding bottles, tableware (plates and mugs) and
storage containers. Epoxy resins are used in protective linings for food and beverage cans and vats.
The scientiﬁc debate on the risks for public health of BPA is focussed on its endocrine-active
properties, which might adversely impact physical, neurological and behavioural development. In
addition, other perturbations of physiology, both in animals and humans, have been brought in
relationship to the endocrine-active properties of BPA. Among these are, e.g. obesity, modiﬁcation of
insulin-dependent regulation of plasma glucose levels, perturbation of fertility, proliferative changes in
the mammary gland possibly related to the development of breast cancer, immunotoxicity and adverse
effects on the cardiovascular system (for an overview, see EFSA, 2006, 2008, 2010; NTP-CERHR,
2008; ANSES, 2013).
Speciﬁcation of the subject
The question of interest resulting from this risk assessment of BPA was: ‘What is the biological
relevance for human health of the observed proliferative and morphological changes in the mammary
gland following exposure to BPA and the possible relevance for the development of breast cancer’?
Speciﬁcation of the effects
To update the risks to public health from BPA exposure, the complex BPA toxicity was re-evaluated
by EFSA in 2015 using a Weight of Evidence (WoE) approach to identify the critical toxicological effects
[EFSA Journal 2015; 13(1): 3978]. The effects on kidney weight were considered critical endpoints and
taken forward to hazard characterisation to assess a reference point (BMDL10) for the derivation of a
health-based guidance value (TDI). As the scientiﬁc evidence for observed reproductive- and
developmental effects, neurological-, neurodevelopmental- and neuroendocrine effects, immune
effects, cardiovascular effects and metabolic effects was not sufﬁcient, they were not taken forward
for risk characterisation, but these effects were included in the uncertainty evaluation.
In the WoE approach used for hazard identiﬁcation, next to the general toxicity effects on kidney
weight, also proliferative and morphological changes in the mammary gland were reported in several
new toxicity studies and considered ‘likely’ (likely refers to 66–100% probability), although no
reference point (BMDL10) could be calculated.
These proliferative responses and possibly enhanced sensitivity to mammary gland carcinogens
seen in animal studies might be of relevance for human health and were therefore included in the risk
assessment.
Collection of data relevant to the problem formulation
Earlier evidence for BPA effects on cell proliferation and differentiation and morphological changes
potentially related to tumour induction in the mammary gland [EFSA Panel on Food Contact Materials,
Enzymes, Flavourings and Processing Aids (CEF), 2010] were supported by new toxicity studies
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published from 2010 onwards. A number of these new laboratory animal studies in rodents (rats and
mice, including a.o. transgenic mouse models and DMBA mammary tumour mouse model) and a
monkey study, have reported effects on mammary tissue (mammary tumour induction, enhancement
of mammary tumour growth and/or proliferative changes in mammary gland) after prenatal, perinatal
and adult exposure to BPA.
Overall, using expert judgement, the CEF Panel concluded that although there were methodological
weaknesses in all these studies with the exception of a US FDA/NCTR subchronic toxicity study, which
was a detailed guideline study conducted in accordance with GLP, they provide further evidence that
BPA may enhance mammary epithelial proliferation in animal models.
However, the proliferative changes in the mammary gland reported in these new studies, including
a non-human primate study, are considered insufﬁcient to conclude that there is a link to cancer
development in later life. Nevertheless, there might be a possible role of BPA in increasing the
susceptibility to mammary gland carcinogenesis.
Relevance of the agent
Although the exact MoA in respect to the reported proliferative changes in the mammary gland is
not clariﬁed, they may well ﬁt with the conclusions of the mechanistic studies in which it is shown that
BPA affects a number of receptor-dependent and independent signalling pathways, resulting in effects
on hormone homeostasis and gene expression as well as cytogenetic and epigenetic effects.
It was concluded in the Panel that no single clearly deﬁned mode of action of BPA can be identiﬁed
that can contribute substantially to the understanding of the potential effects of BPA in humans.
However, given that BPA appears to have multiple modes of action at the cellular level, and at least
some of these MoAs involve cellular responses that are highly conserved across species (e.g. binding
to oestrogen or androgen receptors), the relevance for humans of the variety of effects that have
been reported for BPA in mechanistic studies cannot be totally discounted.
Relevance of the subject
Although there is no convincing evidence that BPA is carcinogenic in animals when exposed to
adults or during pre- and post-natal (during lactation) development, a large number of the animal
studies suggest that BPA can have a proliferative/developmental advancement effect on mammary
tissue, and may also have an effect on tumour growth in animal models, particularly in sensitive
transgenic models or when followed by a treatment with a complete carcinogen (DMBA).
In a large number of rodent toxicology studies, including a study with non-human primates, effects
have been noted of pre- or perinatal BPA exposure on mammary gland morphology, cell proliferation
and modiﬁcation of gene expression. For instance, the architectural modiﬁcations induced by the BPA
in mammary glands of female offspring were transient increases in the total number of epithelial
structures. Moreover, time and dose-dependent modiﬁcations in gene expression proﬁles were
observed after treatment with BPA, e.g. modulated (mainly upregulated) genes related to cell
proliferation, apoptosis and differentiation, cell communication, signal transduction, immunity, protein
metabolism and modiﬁcation. Supportive observations also came from several studies (10) using the
subcutaneous (s.c.) route of administration of BPA, which also indicated that prenatal BPA exposure
results in an increased cell proliferation/apoptosis ratio in normal tissue as well as preneoplastic lesions
of rat mammary gland.
In relation to possible carcinogenic effects of BPA in animals when exposed pre- and post-natally
(during lactation), several studies (5) used the dimethylbenzanthracene (DMBA) mammary tumour
mouse model to assess the effects of fetal or postnatal exposure to BPA on the development of
mammary tumour in adults. Overall, increased susceptibility to development of mammary cancer,
decreased tumour latency and increased tumour multiplicity was reported.
Also, studies were performed in transgenic mouse models, such as an adult knockout mouse model
of mammary neoplasia, showing increased epithelial cell proliferation and hyperplasia in mammary
glands of adult BRCA1* knockout mouse upon BPA exposure via osmotic pumps, In addition, in a
female transgenic MMTV-erbB2/neu mice susceptible to develop mammary carcinoma, BPA treatment
via drinking water resulted in a decreased tumour latency and increased tumour multiplicity, enhanced
tumour volume and higher incidence of lung metastasis.
Also, the US FDA/NCTR subchronic (90-day) toxicity study provided some evidence of a BPA-related
effect in the mammary gland of female rats. Mammary gland duct hyperplasia of minimal severity was
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reported in the female groups examined at Post-natal Day (PND) 21 and in the high-dose female BPA
groups examined at PND 90.
Taken together, as intraductal hyperplasia in the mammary gland is observed in humans and is
considered as a precursor of ductal carcinoma both in rodents and in humans, this lesion is considered
of relevance when studied in animals (e.g. rodents) to predict cancer in the human mammary gland
and is considered as adverse.
Relevance of the effect
Intraductal hyperplasia in the mammary gland is observed in humans and is considered as a
precursor of ductal carcinoma both in rodents and in humans. Therefore, this lesion is of high
relevance to predict cancer in the human and animal mammary gland and is considered as adverse.
Ductal hyperplasia and an increase of the number of Terminal End Buds (TEBs) may be regarded as
supporting evidence for tumour formation along with an increase in the proliferation of epithelial cells.
However, ductal hyperplasia may not always progress to neoplastic lesions but may be reversible.
Therefore, the relevance of these hyperplastic lesions, in the absence of intra-ductal hyperplasia, is
questionable for humans and the level of adversity of these ﬁndings is unknown.
Increased epithelial cell proliferation in the mammary gland of rodents is linked to prolactin, which
is also associated with an increased breast cancer risk in women. Thus, an increase in prolactin levels
constitutes an underlying mechanism in the induction of cell proliferation, which may be indicative and
therefore relevant for tumour promotion in both the human and rodent mammary gland.
In summary, based on the above indicated observations the proliferative and morphological
changes in the mammary gland reported in several toxicity studies with BPA were considered relevant.
Relevance of the conditions
The experimental test species and test conditions were for most studies considered relevant,
although the study reliability (e.g. data reporting, methodology) was considered low or medium for all
studies on BPA-induced proliferative effects.
Although several studies were conducted with the non-relevant subcutaneous route of pre-or
perinatal BPA exposure, supportive observations of increased cell proliferation/apoptosis ratio were
reported in normal tissue as well as preneoplastic lesions of rat mammary gland, while in other studies
with perinatal BPA exposure no such lesions were detected.
The relevance of the ﬁndings in the DMBA mammary tumour model and the sensitive transgenic
models is uncertain because of limited experience with these models.
Uncertainties
The uncertainties related to the induction of proliferative changes in the mammary gland following
BPA administration, i.e. intraductal hyperplasia, epithelial cell proliferation and ductal hyperplasia
(including increase in the number of TEBs), were evaluated taking into account the reliability of the
study results.
For the evaluation of uncertainty, the expert panel reviewed the studies considered in the WoE, and
extracted key information from each study and collated that in a graphical format. The graphs
summarised for each study, the life stage of the animals at treatment onset, duration of treatment and
sampling time for measurements, the doses tested, whether there was a statistically signiﬁcant effect
at any dose, the number of strengths and weaknesses of the study, the Panel’s evaluation of the
reliability of the study and its relevance to the effect of interest.
Some potential sources of uncertainties:
• Several studies with subcutaneous, pre- or perinatal BPA exposure reported on intraductal
hyperplasia in the mammary gland (i.e. an increase in the relative number of ducts lined by
three or more layers of epithelial cells), while in other studies with perinatal BPA exposure no
such lesions were detected.
• While epithelial cell proliferation is a normal physiological process in certain life stages
(pre-/perinatal period, pregnancy) and per se does not lead to tumour formation, it is generally
accepted that under certain pathological conditions such as recurrent tissue damage and repair
the proliferating tissue becomes more susceptible to tumour development. In studies with rats
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treated with BPA and, thereafter, with a well known complete carcinogen (DMBA), as well as in
studies with transgenic mice, increased cell proliferation was reported along with tumour
formation. In case of the study that observed cell proliferation in transgenic mice which
spontaneously develop tumours, the relevance of these ﬁndings to whether proliferative
changes occur at low BPA doses in normal animals was considered medium, taking into
account the increased sensitivity of this mouse model to tumour development.
• Increase in the number of TEBs as well as ductal hyperplasia was reported in several studies
even at very low BPA doses. However, it should be noted that these putative pre-neoplastic
lesions may be reversible and will not in all cases progress to neoplasia.
• In addition, also the study reliability (e.g. data reporting, methodology) was considered low or
medium for all studies on BPA-induced proliferative effects.
Conclusion
In the ﬁnal assessment, the overall likelihood of the BPA-induced proliferative changes in mammary
gland in animals exposed during pre-and postnatal (during lactation) development or up to 90 days
(gavage) was considered ‘likely’, and taken forward for the risk characterisation based on the
consistency of the effect in a number of studies.
The Panel concluded that the health-based guidance value should cover the lowest dose in the
dose range for which the likelihood approaches ‘likely’ from the overall uncertainty evaluation, taking
into account uncertainty of all the evaluated endpoints as well as their relevance and adversity to
humans. The uncertainty evaluation approached ‘likely’ in the (HED) dose range of 100–1,000 lg/kg
bw per day. The Panel therefore decided that the uncertainty regarding the above mentioned effects
at the HED of 100 lg/kg bw per day and higher should be taken into account when establishing a
health-based guidance value by including an extra factor in establishing the TDI. Thus, as the
reference point was 609 lg/kg bw per day based on the mean relative kidney weight and the lower
end of the dose range for which the uncertainty evaluation for other endpoints approached ‘likely’ is
100 lg/kg bw per day, a factor of 6 was applied.
The CEF Panel applied ﬁnally a total uncertainty factor of 150 for inter- and intraspecies differences
(1 for toxicokinetics and 2.5 for toxicodynamics and 10 for intra-species differences), and the
uncertainty factor of 6 (for e.g. mammary gland effects) to establish a temporary Tolerable Daily
Intake (t-TDI) of 4 lg/kg bw per day.
By comparing the t-TDI with the exposure estimates, the CEF Panel concluded that there is no
health concern for any age group from dietary exposure or from aggregated exposure.
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Annex E – FEED
Example from FEEDAP
1. Problem formulation
The scientiﬁc evaluation of feed additives by EFSA includes:
• The safety of the additive for the target animals
• The safety of the additive for the consumer (human health)
• The safety of the additive for the user/worker
• The safety of the additive for the environment
• The efﬁcacy of the additive
The assessment of feed additives is a standardised process, which follows legal guidelines and
guidance documents. The assessment questions are already deﬁned in a standard form in the terms of
reference and the assessment follows a standardised procedure.
The evaluation of the biological relevance of an effect under consideration in the FEEDAP
Panel includes adverse (unwanted) effects and beneﬁcial (wanted) effects on potentially different
species and has to address all aspects indicated above.
The feed additive considered in this example consists of two essential oils derived from steam
distillation of Thymus vulgaris (thyme) and Illicium verum (star anise), quillaja bark powder, crushed
herbs and spices, and other feed materials (EFSA FEEDAP Panel, 2016). Thymol and trans-anethole
are the major components of thyme oil and star anise oil, respectively. Star anise oil may contain the
genotoxic carcinogen alkenyl-benzene derivative estragole in considerable concentrations.
The additive is intended for use in chickens for fattening (the target species) at a dose of 150 mg/kg
complete feed.
Problem formulation at a glance is shown in the following Table.
Agents Effects Subjects Conditions
Additive/single active
substances: trans-anethole
and thymol
Short-term toxicity (mortality,
clinical effects, performance
parameters, haematology,
blood chemistry,
histopathology when needed)
Target species Dietary exposure at
recommended dose in
feed (150 mg/kg feed) –
Establishment of a safe dose
via tolerance studies
(x10 overdosing)
Single active substance:
trans-anethole
Effects on liver enzymes and
histopathology. Liver effects
for trans-anethole in
laboratory animals
Target species,
Consumers
Dietary exposure via
residues (data available from
tolerance study, x10)
Single active substances:
trans-anethole and thymol
Irritation, skin sensitisation Users/workers Exposure by inhalation,
contact, systemic exposure
Single active substances:
trans-anethole and thymol
Short-term effects
(LC50, EC50) and long-term
effects (NOEC)
Terrestrial and aquatic
organisms in the
environment
Exposure via manure
containing residues or non
consumed feed
Single active substance:
estragole
Genotoxicity All subjects See above
Additive/single active
substances: trans-anethole
and thymol
Improving animal
performances
Target species Dietary exposure at the
proposed use level
Digestibility enhancer
Speciﬁcation of the agents
The active substances in the additive were considered to derive mainly from the thyme oil and star
anise oil. The crushed herbs and spices will also contribute to the activity but to a lesser extent.
Thymol and trans-anethole, the major components of thyme oil and star anise oil, represent about
0.2–0.4% and 4–5% of the additive, respectively. Star anise oil may contain the alkenyl-benzene
derivative estragole up to 6% (European Pharmacopoeia, 2005).
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Speciﬁcation of the effect(s)
Adverse effects
Liver effects: Hepatotoxic effects have been reported for trans-anethole when administered to rats
(WHO, 2000, EFSA FEEDAP Panel, 2011a). A no observed effect level (NOEL) of 300 mg/kg bw per
day was derived from a 90-day study based on elevated serum activity of c-glutamyl transferase
observed at 600 and 900 mg/kg bw per day in male and female rats, respectively (Minnema 1997).
The NOEL was considered as an appropriate point-of departure to derive an acceptable daily intake
(ADI) of 0–2.0 mg/kg bw per day (by applying an uncertainty factor of 200 to allow for deﬁciency in
the long-term study; WHO, 2000).
Genotoxicity: Estragole was demonstrated to be genotoxic in several in vitro and in vivo short-term
assays and carcinogenic in mice after oral administration. As such, estragole has the ability to induce
cancer in the exposed organisms through a genotoxic MoA; as a genotoxic agent, it is considered also
to induce mutations in germ cells of humans and animals, with negative effects for the reproduction.
Both effects are clearly deﬁned as adverse and could be relevant for target animals, consumer, user
and environment, if the conditions of the exposure to the compound allow the adverse outcome to
occur.
Positive effects
An assessment of the efﬁcacy of the feed additive is needed because the applicant claims that it
increases the animal performance and digestibility of feed in chickens for fattening. Relevant
performance parameters suitable for the assessment are the determination of feed intake, body weight
gain and feed to gain ratio. Trials to demonstrate the efﬁcacy of feed additives in vivo should be
performed according to the guidance published by EFSA (EFSA FEEDAP Panel, 2011b).
Speciﬁcation of the subjects
Adverse effects
The subjects of adverse effects are: (i) the target animal fed diets containing the additive (chickens
for fattening), (ii) the consumer of the food products from chickens fed the additive, (iii) the workers
handling the additive and (iv) terrestrial and aquatic organisms in the environment.
Positive effects
The subjects of positive effects are the target animals fed diets containing the additive (chickens
for fattening).
Speciﬁcation of the conditions
trans-Anethole and estragole are part of a diet for chickens. Thus, the compounds enter the body
of the animals by oral uptake. Possible residues of the additive/active substances in the meat from
chickens fed the additive are taken up by humans with their food. Users and workers, handling the
additive or the feed with the additive may also be exposed to the compound via the skin, eye,
mucosae or lung. Organisms of the environment may be exposed to the compounds or their
metabolites via the manure of the chicken, which is used as a fertiliser and could contain residues of
the additive.
Collection of data relevant for the problem formulation
The assessment is based on evidence/data provided by the applicant in the form of a technical
dossier, prepared following the provisions of Regulation (EC) No 429/2008 and relevant Guidance
documents (EFSA, 2008; EFSA FEEDAP Panel, 2011b, 2012a,b,c).
These data included the characterisation of the additive, two tolerance studies in chickens for
fattening, residue data in meat and liver from chickens fed the additive at 10x the recommended dose,
ﬁve long-term and six short-term efﬁcacy studies.
Tolerance studies are designed as short-term toxicity studies to assess adverse effects of the
additive in the target species at the proposed conditions of use and at x-fold (10x, 100x) the
recommended dose. The endpoints considered in tolerance studies are: mortality, clinical effects,
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zootechnical parameters (body weight, average daily gain, average daily feed intake, feed conversion
ratio), haematological and blood chemistry parameters, gross pathology, organ weight and
histopathology (if needed).
Efﬁcacy studies are designed to demonstrate the efﬁcacy of the additive at the lowest
recommended dose. A signiﬁcant effect on the performance parameters consistently observed in three
long-term studies (feed intake, body weight gain and feed to gain ratio) allows the conclusion that the
additive has the potential to be efﬁcacious.
Assessment of the collected data sets for biological relevance
trans-Anethole
Relevance of the agents
Adverse effects
trans-Anethole speciﬁed as a major component is of the additive is considered, at least in part,
responsible for potential adverse effects of the additive. Literature data are available for the adverse
effects of the pure compound trans-anethole (effects on liver enzymes and histopathology, liver toxicity
in rat, WHO).
If adverse effects were observed in tolerance studies performed with the additive, it would not be
possible to conclude which agent(s) is (are) considered responsible for the observed effects. Besides
trans-anethole, other additive ingredients or components of the essential oils could also be responsible
for potential adverse effects of the additive.
Positive effects
If a beneﬁcial effect of a feed additive is based on economic parameters relevant for the farmer
and not the animal, it can be demonstrated by a statistical signiﬁcant increase of performance
parameters. The efﬁcacy of the feed additive containing thymol and trans-anethole as part of essential
oils and thus its biological relevance was demonstrated by a statistically signiﬁcant increase (p < 0.05)
of the performance parameters indicated above, however, there is no direct evidence that this effect is
due only to these two components.
Relevance of adverse effects of trans-anethole
Relevance of the methods
Possible adverse effects for target species were assessed in tolerance studies, where the additive
was fed at the proposed conditions of use and at 10-fold the recommended dose. These tolerance
studies included endpoints which could also detect adverse effects on the liver (liver weight, liver
enzymes, histopathology.), which were observed in the rat studies. Since no adverse effects were
observed at the proposed conditions of use and at up to a 10-fold of the recommended dose, it was
concluded that the additive and the active substances are well tolerated by the target animals.
Relevance for the target species
Liver toxicity was observed in sub-chronic and chronic toxicity studies in rats treated with
trans-anethole. These effects are not speciﬁc for rats and can be extrapolated to other species. They
are therefore considered relevant for the target species, i.e. chicken for fattening. However, the
conditions of chronic studies could be of limited relevance for target species with a short life span as is
the case for the target animals of this example.
Tolerance studies performed with the additive under assessment are relevant to assess adverse
effects in the target species. Liver effects were not observed in tolerance studies in chicken for
fattening. The reason might be that the exposure level of trans-anethole as part of the feed additive
was not high enough. Assuming that the additive is supplied at the proposed use level of 150 mg/kg
and considering the default values of feed intake and body weight for chickens for fattening (EFSA
FEEDAP Panel, 2012d), it can be calculated that this dose level would result in an exposure of
0.3 mg/kg bw of trans-anethole per day. In the experiment with the 10-fold overdose of the
additive, this value would be 3 mg/kg bw per day. The NOEL derived from the 90-day rat study was
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300 mg/kg bw, which provides a 1,000-fold margin of safety compared to the chicken exposed with
the proposed dose level of the additive (150 mg/kg feed) and a 100-fold margin for the experiment
with the 10-fold overdose. Thus, the liver toxicity of trans-anethole is not relevant for the target
animals because the exposure level is not high enough.
Relevance for the consumer
trans-Anethole is metabolised along the same three major pathways in rat, mice and humans.
Therefore, hepatotoxicity in rats was considered relevant to humans, if they are exposed to
trans-anethole via residues.
The applicant provided evidence that residues of trans-anethole could not be detected in meat from
chickens fed the additive at 10 times the recommended dose (limit of detection, 0.1 lg/g). Exposure
of consumers to trans-anethole can therefore be excluded. The presence of trans-anethole in chickens
feed at the recommended dose level will therefore not be of biological relevance for the consumer.
Relevance for the user
trans-Anethole is irritating to skin and may cause risk of serious damage to eyes after direct
exposure. Handling of the compound during preparation of the additive could therefore provide
adverse effects to workers. Besides trans-anethole, the feed additive contains a variety of other
compounds, which have the potential to irritate eyes and mucous membranes and to cause allergies
upon contact with skin and respiratory organs.
Relevance for the environment
trans-Anethole present in the feed of chicken for fattening will be extensively metabolised to inert
compounds, excluding possible biologically relevant effects on the environment.
Relevance of positive effects for the target animals
The applicant claims that the feed additive increases the performance of chicken for fattening. This
effect was proven in experimental trials with the target animals. Statistical parameters are used to
conﬁrm this claim. The effect cannot be attributed to certain compounds of the complex composition
of the feed additive. The effect is of economical relevance for the farmer, because it reduces the costs
for the meat production. The effect is not relevant for the animal.
Estragole
Relevance of the agent
A battery of standardised test systems is available to prove the genotoxicity and carcinogenicity of
chemicals. The EFSA guidance on genotoxicity testing strategies applicable to food and feed safety
recommends (EFSA Scientiﬁc Committee, 2011a,b) ‘a step-wise approach for the generation and
evaluation of data on genotoxic potential, beginning with a basic battery of in vitro tests, comprising a
bacterial reverse mutation assay and an in vitro micronucleus assay. (. . .) In case of positive in vitro
results, review of the available relevant data on the test substance and, where necessary, an
appropriate in vivo study to assess whether the genotoxic potential observed in vitro is expressed
in vivo is recommended. Suitable in vivo tests are the mammalian erythrocyte micronucleus test,
transgenic rodent assay, and Comet assay. If the in vivo assay results in positive effects, the substance
should be considered as an in vivo genotoxic agent. (. . .) If a two year carcinogenicity study in rodents
results in a signiﬁcant increase in the formation of malignant tumours compared to the control, the
compound is considered as an animal carcinogen and possible human carcinogen’.
Evidence exists for the genotoxicity of estragole in V79 cells, CHO cells as well as rat and human
hepatocytes in vitro and ex vivo, after oral treatment of rats with estragole (Martins et al., 2012).
Estragole was also clearly genotoxic in transgenic mouse and rat strains (Suzuki et al., 2012). Clear
evidence for the carcinogenicity of estragole comes from studies in mice (Drinkwater et al., 1976).
The MoA for the genotoxicity of estragole is the oxidation to 1-hydroxyestragole by CYP1A2 and
conjugation with sulfate to 1-sulfooxyestragole by SULT1A1 (Wiseman et al., 1985). Spontaneous
abstraction of SO4
2 releases a carbocation, which form adducts with DNA and proteins. The formation
of such adducts was demonstrated in the liver of mice and other mammalian species including human
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liver specimens in vitro (Phillips et al., 1984; EMA, 2014). On the basis of this mechanism, estragole is
a genotoxic hepatocarcinogen and the formation of DNA adducts is the ﬁrst pre-initiation step.
Although hepatocarcinogenicity of estragole has only been demonstrated in mice, the presence of the
enzymes involved in the critical steps of tumour initiation is not restricted to mice and makes it likely
that the same MoA takes place in other species including birds and humans (EMA, 2014). In the
absence of evidence showing that estragole does not reach germ cells, it has to be assumed that
estragole can exert its genotoxic effects in both somatic and germ cells.
Relevance of adverse effects of estragole
Although there is a debate about the question whether or not a threshold dose exists for genotoxic
compounds, it is generally accepted that the exposure of humans and animals to carcinogenic
compounds should be avoided as much as possible. With respect to the food and feed industry this
means that, whenever possible, carcinogens should not be added to human food or animal feed.
Therefore, the presence of the genotoxic and carcinogenic potential of estragole in the feed of farm
animals, which serve as food for humans is of critical relevance for the risk assessment.
Relevance of the subjects and conditions
Relevance for the target animal
The additive is intended as a feed additive for chicken for fattening. These animals have a short life
span, which makes it very unlikely that they develop cancer as a result of the exposure to the
carcinogenic compound in their diet. These animals are also not used for reproduction. Thus, although
genotoxicity is a strong adverse effect, the biological relevance for the target animals of this example
(chicken for fattening) is limited.
Relevance for the consumer
For the assessment of the safety for the consumer, the critical question relates to whether the
carcinogen (estragole) is transferred to human food obtained from chickens fed with the additive.
Therefore, the ADME proﬁle of the genotoxic compound has to be investigated and analytical data of
possible residues in edible tissues of the chicken are needed, performed with methods being sensitive
enough to detect very small concentrations of the critical compound and its active metabolites. If the
compound is not absorbed or totally metabolised to innocuous compounds and if the absence of the
genotoxic compound itself or genotoxic metabolites thereof can been proven, the use of the genotoxic
compound in feeds may also be of no biological relevance for the consumer. However, it is often
difﬁcult to demonstrate the absence of the genotoxic compound or its metabolites in products derived
from animals fed with the additive, for technical reasons (the sensitivity of the analytical method
applied results in an ‘analytical threshold’). The addition of an essential oil containing estragole is
therefore of biological relevance for the consumer.
Relevance for the user
Genotoxic compounds in feed additives may create a concern for the safety of the user, if any
contact with such compounds cannot be avoided. Exposure to estragole while handling the compound
can occur mainly via skin contact and inhalation of the star anise oil. The presence of estragole in feed
of chicken for fattening represents a biologically relevant hazard for users handling the additive, which
is of biological relevance.
Relevance for the environment
Estragole is a naturally occurring compound in plants present in the European environment.
Because of the relatively low concentration in the feed of chickens for fattening and the metabolism in
the target animal, possible residues of estragole in the excreta of the birds will not measurably
increase the concentration of this compound in the environment. For these reasons, the presence of
estragole in the feed of chickens for fattening is considered without biological relevance for the
environment.
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Overall conclusion
During problem formulation, the presence of estragole was identiﬁed as a hazard associated with
the exposure to the additive, particularly for consumers potentially exposed to residues of the additive
via products of animal origin (meat) and users exposed via inhalation. Considering that the intentional
addition of compounds with genotoxic-carcinogenic properties to the food chain via feed additives
should be avoided (minutes of the 109th Plenary meeting of the FEEDAP Panel), the applicant
reformulated the additive to remove estragole from the additive.
Uncertainties
Adverse effects
The MoA for the genotoxicity of estragole is the oxidative conversion to 1-hydroxyestragole, which
is further conjugated with sulfate to the ultimate carcinogen (Boberg et al., 1983). After long-term
treatment of mice, the animals developed signiﬁcant increases in the incidence of hepatocarcinomas.
The high sensitivity of mice to develop liver cancer limits the extrapolation of this effect to humans.
However, it was demonstrated that the metabolism of estragole leading to DNA adducts in the liver is
not restricted to mice and occurs also in other species including birds and humans. The carcinogenicity
of estragole in mice can therefore be taken as evidence for a possible carcinogenic effect of estragole
in other species including humans.
It was demonstrated that the percentage of 1-hydroxyestragole formed after application of
estragole to mice and rats increases with the administered dose. At low concentrations, estragole is
mainly metabolised via alternative pathways to non-genotoxic compounds (Anthony et al., 1987).
Taken into consideration that the concentration of estragole residues in the tissue of chicken treated
with the additive is very low, this fact increases the uncertainty that estragole residues represent a
biologically relevant hazard for the consumer.
Relevant adverse effects of trans-anethole and other non-genotoxic irritating compounds of the
feed additive are restricted to the user/worker. These effects depend on the mode and level of
exposure and thus to the safety precautions which are in place at working facilities.
Positive effect
The feed additive has the capacity to increase the performance of chicken for fattening, providing
positive economic effect for the farmer. Any such effect exceeding the costs of the additive can be
considered as relevant. However, the animal itself will not beneﬁt from this positive effect.
Considerable uncertainty exists about whether such effects might be attributed to certain
compounds of the feed additive or they rather reﬂect an additive effect of the mixture.
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Annex F – GMO
Scientiﬁc Opinion on application EFSA-GMO-NL-2007-45 for the placing on
the market of herbicide-tolerant, high-oleic acid, genetically modiﬁed
soybean 305423 for food and feed uses, import and processing under
Regulation (EC) No 1829/2003 from Pioneer (EFSA GMO Panel, 2013)
Assessment strategy
The EFSA GMO Panel was requested to carry out a scientiﬁc assessment of soybean 305423
(Unique Identiﬁer DP-305423-1) for food and feed uses, import and processing in accordance with
Articles 6(6) and 18(6) of Regulation (EC) No 1829/2003,4 i.e. to assess whether the import of
soybean 305423 and/or any of its derived products in the EU would result in additional safety concerns
to animal and human health or to the environment with respect to conventional soybean. Since the
scope of this application excludes cultivation in the European Union the environmental risk assessment
(ERA) is limited to the consequences of accidental spillage of imported soybeans and to the
dissemination of faeces of animals feeding soybean 305423.
The risk assessment strategy for genetically modiﬁed (GM) plants and derived food and feed is
described in EFSA guidelines for the risk assessment of GM plants and derived food and feed (EFSA
GMO Panel, 2011), the ERA of GM plants (EFSA GMO Panel, 2010), and the post-market environmental
monitoring (PMEM) of GM plants (EFSA GMO Panel, 2010, 2011). It is based on comparative
assessment approach, that is to compare GM plants and derived food and feed with their appropriate
comparators by appropriate methodologies and tools. The underlying assumption is that traditionally
cultivated crops have a history of safe use for consumers and/or domesticated animals. It is designed
to characterise the intended effects of the genetic modiﬁcation and to identify possible unintended
effects associated to it. Expected and unexpected differences observed on a series of plant
characteristics between the GMO and its comparator will then be assessed as regards their biological
relevance for humans and animals from the nutritional, toxicological and environmental viewpoint
(EFSA GMO Panel, 2010, 2011).
Speciﬁcation of the agent
1) The GM plant itself: Soybean 305423
Soybean 305423 was transformed:
• to express the Glycine max-hra (gm-hra) gene coding for a modiﬁed version of the
GM-HRA protein conferring tolerance to acetolactate synthase (ALS)-inhibiting herbicides;
• to express a fragment of the endogenous fad2-1 gene resulting, through RNA
interference, in the silencing of the endogenous fad2-1 gene, which leads to a
decreased level of the omega-6 fatty acid desaturase and a high-oleic acid phenotype.
2) The newly expressed protein as such: GM-HRA
This protein is expressed in soybean 305423 as intended trait of the genetic modiﬁcation. Two
forms of this protein are considered:
a) The GM-HRA protein expressed in soybean 305423.
b) The equivalent GM-HRA protein expressed in a recombinant microbial system (E. coli) used in
toxicological studies.
Speciﬁcation of the subjects
• Humans who are exposed to the agents through the consumption of soybean 305423 and
derived food.
• Animal species that are exposed to the agents through the consumption of soybean 305423
and derived feed.
4 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. Ofﬁcial Journal of the European Communities, L268, 1–23.
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• Ecosystems, including soils, could also be exposed to the GM plant but, considering the scope
of the application that excludes cultivation and the nature of the crop, the level of exposure is
likely to be very low.
Speciﬁcation of the effects
In soybean 305423, the genetic modiﬁcation is intended to introduce two new traits (intended
effects of the genetic modiﬁcation): herbicide tolerance, via the expression of a endogenous enzyme
modiﬁed for herbicide-resistance; and high-oleic acid phenotype, via RNAi-mediated modulation of the
plant fatty acid metabolic pathway.
Intended effects are known a priori to occur, while the size of their change might need conﬁrmation.
• increase in oleic acid contents in soybean 305423 compared to conventional soybean, which in
turn might change the prevalence of oleic acid in the diets of animals and humans;
• tolerance to ALS-inhibiting herbicides, likely to lead to a change of weed control management
of soybean 305423, which in turn might lead to changes in plant metabolism and the presence
of ALS-inhibiting herbicides residues in the plant.
Unintended effects are not known a priori but may include:
• changes in the agronomic and phenotypic characteristics (e.g. plant height, seed weight) of
soybean 305423 compared to its comparator, which may be indicative of changes in the
metabolism;
• changes in the level of endogenous components of soybean 305423 compared to its
comparator, which in turn may affect the nutritional balance of animal and human diets or
induce toxicological effects (dependent on the speciﬁc toxic compounds whose level has
changed);
• toxicological and allergenic effects of the newly expressed protein GM-HRA;
• increased allergenicity of soybean 305423 compared to conventional counterpart (soybean is
considered a common allergenic food [European Commission, 2007]).
• the presence of open reading frames (ORFs), which might translate into peptides raising safety
concern.
Indirect and/or delayed effects may also result from the changes in agricultural practices induced
by the introduction of the GM plant but such effects are not relevant in the context of this application
that does not cover cultivation in the EU.
The introduction of soybean 305423 on the market (through the import and processing of
materials, beans and/or meals) could replace already used conventional soybeans in animal feeding
and human use.
Under this scenario, the safety of soybean 305423 was assessed as regards its intended trait
(newly expressed protein and modiﬁed fatty acid proﬁle) and unintended changes observed.
Considering the modiﬁed fatty acid proﬁle of soybean 305423, the impact of this replacement on
the diet and in feedstuff formulation was assessed by an exposure assessment. For the oil derived
from soybean 305423 (the main product for human consumption), a replacement dietary exposure
assessment was performed to investigate whether unbalanced diet for humans might result from
soybean 305423 oil consumption, including investigations on the changes in the level of fatty acids for
which nutritional recommendations exist.
Possible impacts of changes in the level of endogenous toxic (antinutritional) compounds in
soybean 305423 compared to conventional counterparts of relevant for food and feed safety are
assessed in the application.
Speciﬁcation of the condition(s)
Conditions that should be implemented to assess the effects of the agents on the subjects are
described in guidance documents (EFSA, 2011).
These include:
• a set of ﬁeld trials comparing the GM plant, its conventional counterpart (i.e. the genetically
closest line differing from the GM plant only for the genetic transformation) and a range of
commercial reference varieties (to establish natural variability); ﬁeld trials should be carried out
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under representative receiving environments; agronomic, phenotypic and compositional
characteristics are measured and are subject to a difference and equivalence test;
• a 28-day rodent study on the E. coli GM-HRA protein (according to OECD TG 407);
• in vitro pepsin- and pancreatin-resistance tests on the on the E. coli GM-HRA protein;
• animal studies on the whole food/feed from soybean 305423 (a 90-day rodent study according
to EFSA Scientiﬁc Committee, 2011a,b an OECD TG 408; a 12-week study in laying hens and a
77-day study in pigs, according to ad hoc protocols);
• allergenicity testing on whole soybean extracts (human sera);
• Dietary intake/exposure scenarios for intended changes in oleic acid (ad hoc protocol).
Data collection
The risk assessment strategy for GM plants and derived food and feed proposed seeks to deploy
appropriate approaches to compare GM plants and derived food and feed with their respective
comparators. The underlying assumption of this comparative approach is that traditionally cultivated
crops have gained a history of safe use for consumers and/or domesticated animals and the risk
assessment primarily focused on new proteins and/or changes in composition of the GM plant. The
starting point of the data collection aims at identifying similarities and differences between the GM
plant and its conventional counterpart (see above).
Data were provided by the applicant in the form of a technical dossier.
Data provision was based on requirements by EFSA GMO guidance documents (EFSA Guidance for
risk assessment of food and feed from GM plants; EFSA GMO Panel, 2010, 2011).
Ad hoc additional data asked from EFSA and/or provided by the applicant. These were necessary to
corroborate and to further clarify information on:
1) Agents: further details on RNA interference process in soybean 305423; on the structural
and enzymatic activity of the newly expressed protein GM-HRA; toxicological proﬁle and
allergenicity of newly expressed protein GM-HRA.
2) Identiﬁcation of the effects: clariﬁcation on the outcome of comparative analysis
assessment (agronomic and phenotypic characteristics and particularly compositional
analysis) and possible biological effects (nutritional impact) of these on consumers/animals.
3) Identiﬁcation of conditions: comparator used in comparative assessment studies;
statistical methodology used in comparative assessment studies; test conditions in
toxicological and animal feeding studies; allergenicity testing of soybean extracts on human
sera; dietary exposure scenarios in humans and animals.
Data included:
• a molecular characterisation, which provides information on the structure and expression of
the insert(s) and on the stability of the intended trait(s);
• a comparison, under representative ﬁeld conditions, of agronomic, phenotypic and
compositional characteristics between the soybean 305423 and its conventional counterpart
(ﬁeld trials, in accordance to EFSA Guidance);
• a toxicological assessment of the newly expressed protein GM-HRA;
• An assessment of potential allergenicity, of the newly expressed protein GM-HRA as well as of
the whole food derived from the GM plant by comparing the allergen repertoire with that of its
appropriate conventional counterpart(s);
• a nutritional assessment to evaluate whether food and feed derived from a soybean 305423 is
not nutritionally disadvantageous to humans and/or animals, in particular on fatty acid proﬁle
of soybean 305423.
Data evaluation for each data set
Relevance of the agents
GM plant: the soybean 305423 used in the assessment is relevant for the assessment, this having
been substantiated by data characterising the transformation event in soybean (sequence, expression
of the insert, stability of inserts).
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Newly expressed protein: GM-HRA
a) The GM-HRA protein expressed in soybean 305423 was fully characterised by experimental data.
b) An equivalent GM-HRA protein expressed in a recombinant microbial system (E. coli): was fully
characterised by experimental data, demonstrated to be equivalent to the plant protein and
therefore considered adequate for toxicological studies.
Relevance of the subjects
Some limitations were identiﬁed:
Humans: The dietary intake and exposure scenario used to support the nutritional assessment for
edible oil were based on UK population only.
Animals: Experimental animals were used (toxicological study on the new protein); possible
extrapolation to humans/other species could constitute an uncertainty.
Relevance of the effects
To go beyond the analysis of statistical differences between the GM plant and its conventional
counterpart and to put such differences into the context of the natural variation of the measured
endpoints among conventional soybean varieties grown under the same conditions as the GM plant
and its conventional counterpart, a test of equivalence is carried out (see box). Effects were identiﬁed
and analysed as for their relevance for further assessment, based on the outcomes of both the
difference test and the equivalence test in the comparative assessment and of the nutritional and
toxicological studies.
1. Increase in oleic acid and MUFA in GM soybean compared to comparators
• Is the effect in itself adverse/positive: not adverse, might be beneﬁcial.
• Is the effect essentially linked to an adverse outcome: NO, these fatty acids are normal diet
constituents.
• Is it directly or indirectly linked to a(n) adverse/beneﬁcial outcome? Possible
(dietary perturbations).
• Signiﬁcant size of the effect: YES (e.g. oleic acid goes up from 20% to almost 80%).
RELEVANT FOR FURTHER ASSESSMENT ? Exposure assessment of European populations
2. Decrease in n-6 PUFA (linoleic acid) in GM soybean compared to comparator
• Is the effect in itself adverse/positive: might be adverse.
• Is it directly or indirectly linked to a(n) adverse/beneﬁcial outcome? YES, deﬁciency in
PUFA. Linoleic acid (LA) is the main dietary n-6 PUFA in the human diet. Deﬁciency in PUFA is
associatedwith clinical symptoms (EFSA NDA Panel, 2010). EFSA has proposed an adequate
intake (AI) for LA of 4 E %, based on the lowest estimated mean intakes of the various
population groups from a number of European countries, where LA deﬁciency symptoms are
not present. This AI corresponds to 9 g linoleic acid/day for an energy intake of 2,000 kcal.
• Signiﬁcant size of the effect: YES (e.g. for C18:2, the level decreases from 50% to less than
10%).
RELEVANT FOR FURTHER ASSESSMENT ? Exposure assessment of European populations
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3. Changes in odd fatty acid chain in GM soybean compared to comparator
• Is the effect in itself adverse/positive: Not adverse, these fatty acid are a normal diet
constituent.
• Is it directly or indirectly linked to a(n) adverse/beneﬁcial outcome? Possible (dietary
perturbations).
• Signiﬁcant size of the effect: YES (statistically).
RELEVANT FOR FURTHER ASSESSMENT ? Exposure assessment of European populations
4. Changes in levels of calcium, zinc and glycitin and related total glycitein
equivalents; trypsin inhibitor
• Is the effect in itself adverse/positive: Not adverse, these are a normal diet constituent.
• Is it directly or indirectly linked to a(n) adverse/beneﬁcial outcome? Possible.
• Signiﬁcant size of the effect: YES from the statistical point of view (different and non-
equivalence demonstrated or more likely to occur than not). These differences might be
indicative of possible unintended effects of the genetic transformation but considered to
need further assessment to conclude on the safety and nutritional characteristics of
soybean 305423 and derived products. As regards calcium, zinc, glycitin and related total
glycitein equivalents this was based on the knowledge on the biochemical roles of these
endpoints in humans and animals as well as on the consideration that the differences in the
levels of these endpoints observed between soybean 305423 and its conventional
counterpart are of limited magnitude. These differences are therefore likely determining a
negligible impact on the safety and nutritional characteristics of this GMO and derived
products for humans or animals as compared to other soybean varieties. Regarding the
trypsin-inhibitor activity, it is noted that the value for this antinutrient is lower than the one
observed in conventional counterpart, and therefore considered not to represent a concern
for safety.
Here, the assessment of biological relevance focused on implications for food and feed safety
and was based on the outcomes of the difference test, of the equivalence testing as well as
expert judgement.
NOT RELEVANT FOR FURTHER FOOD AND FEED ASSESSMENT
5. Allergenicity of the newly expressed protein GMHRA: NO EFFECTS: no indication
that the protein is allergenic (source, bioinformatics etc.)
• Is the effect in itself adverse/positive: the potential effect could be negative; not applicable
here.
• Is it directly or indirectly linked to a(n) adverse/beneﬁcial outcome? The potential effect
could be linked to an adverse outcome; not applicable here.
• Signiﬁcant size of the effect: not applicable here.
NOT RELEVANT FOR FURTHER ASSESSMENT
6. Increased allergenicity of the whole soybean 305423 plant compared to
conventional comparators: NO EFFECT: no change in 2-D immunoblot patterns; no
differences at ELISA analyses
• Is the effect in itself adverse/positive: the potential effect could be negative; not applicable
here.
• Is it directly or indirectly linked to a(n) adverse/beneﬁcial outcome? The potential effect
could be linked to an adverse outcome; not applicable here.
• Signiﬁcant size of the effect: not applicable here.
NOT RELEVANT FOR FURTHER ASSESSMENT
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The GMO Panel concludes that the composition of soybean 305423 differs from that of the
conventional counterpart in its fatty acid proﬁle, in the presence newly expressed protein, the levels of
minerals zinc and calcium, of the isoﬂavone glycitin and in trypsin inhibitor activity. The variations in
the fatty acid proﬁle and the presence of newly expressed protein GM-HRA protein in soybean 305423
are consistent with the objective of the modiﬁcation The safety assessment of GM-HRA identiﬁed no
concerns regarding potential toxicity and allergenicity and there are no indications that the overall
allergenicity of soybean 305423 has changed. Nutritional assessment on soybean 305423 oil and
derived food products did not identify concerns on human health and nutrition, and there are no
concerns regarding the use of feeding stuffs derived from soybean 305423. The GMO Panel considers
that that the soybean 305423, as described in this application, is as safe as its conventional
counterpart with respect to potential effects on human and animal health and the environment in the
context of the scope (EFSA GMO Panel, 2013).
Relevance of the conditions
Field trials: in accordance to EFSA guidance (EFSA GMO Panel, 2010, 2011).
Toxicological studies (28-day study on the newly expressed protein GM-HRA; 90-day toxicity study
in rats on the whole food/feed from soybean 305423: compliant with standard OECD protocols and, as
regards the 90-day study, to EFSA Scientiﬁc Committee, 2011a,b).
Animal feeding studies (broiler, laying hens, pigs): ad hoc, not standardised protocols were
followed; these were considered adequate by the EFSA GMO panel.
Exposure assessment: ad hoc study protocol was used. This was considered adequate by the EFSA
GMO Panel (EFSA GMO Panel, 2013).
Uncertainties
1) General assumption for comparative assessment: The underlying assumption of this
comparative approach is that traditionally cultivated crops have gained a history of safe use for
consumers and/or domesticated animals.
2) Use of the microbial protein as a surrogate of the plant protein: The E. coli-derived GMHRA
protein was fully characterised by experimental data, found to be similar to the plant protein
and considered adequate for toxicological studies; however, some differences were identiﬁed
between the microbial surrogate protein and the plant protein (the puriﬁcation process of the
microbial protein included the cleavage of the His-tag with thrombin; the resulting microbial
GM-HRA protein has an additional glycine residue at the N-terminus compared with the mature
GM-HRA protein expressed in soybean 305423 leaves). Not considered limitative, just noted in
the scientiﬁc opinion.
3) Exposure scenarios for fatty acids: based on UK database only, not representative of the whole
EU population. This was considered relevant and it was suggested, in the post-market
monitoring (PMM) to focus on the collection of consumption data for the European population.
Use of statistical equivalence testing in the comparative analysis of GMOs
The comparative analysis of the characteristics of the GM plant and its comparator(s) grown
under ﬁeld trial conditions is a pillar of the risk assessment of GMOs, as explained in EFSA GMO
Panel, 2011 and Regulation (EU) No 503/2013.
The comparative assessment requires the simultaneous application of two complementary tests
on a set of compositional, phenotypic and agronomic characteristics:
• The test of difference to verify whether the biological system modiﬁed by the genetic
modiﬁcation (i.e. the plant containing the transformation event, or GM plant is different
from its comparator(s) and has therefore the potential to cause adverse effects.
• The test of equivalence to verify whether the agronomic, phenotypic and compositional
characteristics of the GM plant fall within the range of natural variation. Such a range is
deﬁned by limit values, known as equivalence limits, which can be established either on the
basis of existing knowledge, when available, or on the basis of experimental data obtained
from non-GM reference varieties with a history of safe use included in the ﬁeld trial (EFSA
GMO Panel, 2010, 2011). GMO risk assessment experience has shown that equivalence
limits have almost never been established. Therefore commercial varieties are routinely
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included in the ﬁeld trial to allow a direct comparison of the GMO with the commercial
varieties, minimising confounding effects. Such an approach allows evaluating if the GMO’s
characteristic different from that of the comparator falls within the observe range of natural
variability (the difference is acceptable), or if it falls outside (needing further assessment).
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Annex G – NDA
Case study of biological relevance in the area of health claims: Application
for substantiation of a health claim related to: Yestimun® and defence
against pathogens in the upper respiratory tract (EFSA Journal 2013;11
(4):3159)
Assessment strategy
b-Glucans are dietary ﬁbres that have been shown to have immunomodulatory activity in animals
and humans after oral administration. Common colds are caused by viruses, which are pathogens that
are eliminated by the body’s defence mechanisms. By virtue of the effect of b-glucans on the immune
system, the ﬁbres may support defence against pathogens in the upper respiratory tract.
The food, which was the subject of the claim, that the NDA Panel was requested to evaluate, was
Yestimun®, i.e. (1,3)-(1,6)-b-D-glucan produced from brewer’s yeast cell wall (100% Saccharomyces
cerevisiae), and the claim was that this food would support the defence against pathogens in the
upper respiratory tract.
The NDA Panel needed to judge the claimed effect according a number of criteria:
1) Speciﬁcation of the agent: is the food sufﬁciently characterised to evaluate the claimed
effect,
2) Speciﬁcation of the subjects: Which is the target group for the claimed effect,
3) Identiﬁcation: Is the claimed effect in itself a relevant health effect, i.e. is it biologically
relevant, and
4) Speciﬁcation of the conditions: Is the in information based on human intervention studies
and other information. Are the studies, on which the applicant wants to base the claim of
glucans supporting defence to respiratory infection, sufﬁciently powered and are measures
performed according accepted standards and is statistical analysis done appropriately. As
long as common cold could be attributed to infection with an infectious agent, such
information would be useful. Information on other respiratory conditions that are not
attributable to infection is not useful. Information on immune parameters, assessed in
humans, animals, or in vitro systems, can only provide supportive or mechanistic
information, but in the absence of a substantiated effect on defence do not provide any
scientiﬁc evidence for the substantiation of the claim. Does a biological effect occur after
ingestion of the glucan; reduction of an already evident infection is beyond the scope of
health claims on food, such effects would be considered as therapeutic.
Data collection
For the substantiation of the claim, three randomised controlled intervention studies were available.
The primary endpoints were reduction in the number of common cold episodes per subject during the
study periods, whereas secondary outcomes were severity of common cold episodes, duration of cold
episode and the use of antibiotics and analgesics. The applicant provided information on the incidence
of common cold.
Data evaluation
The NDA Panel considered that the food was sufﬁciently characterised for the purpose of evaluating
the claimed effect.
In addition, the NDA Panel considers that supporting defence against pathogens in the upper
respiratory tract, as measured by episodes of common cold, is in itself a beneﬁcial physiological effect
and therefore biologically relevant. In order to substantiate the claim, a statistically signiﬁcant decrease
in common cold episodes, if adequately proven with adequate conﬁdence limits, would have been
sufﬁcient to substantiate the claim.
For the substantiation of health claims, the NDA Panel requires human data, notably intervention
studies in humans. The target population is the general population and the subjects in the study, i.e.
healthy individuals, represent the target population.
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The evidence provided did not establish the validity of questionnaires and criteria used to assess
the incidence or the severity of common cold episodes. The power of the studies were likely adequate
to observe effects on the primary endpoints. However, in one of the studies post-hoc analyses were
performed based on episodes that occurred in the winter months (November to March, ﬁrst half of the
study) to avoid the potential error that might have arisen owing to possible misdiagnosis of allergic
rhinitis as common cold infections during the summer months. While this notion is understood, the
post-hoc selection of the time windows for calculation of possible effects was not accepted as valid. In
another study, statistical analysis did not account for the multi-centre design of the study.
Overall conclusion
In the judgement of the Panel, an effect on incidences of common cold, if appropriately shown to
be statistically signiﬁcant, would have been relevant for the purpose of substantiating the claim.
However, even if statistically signiﬁcant differences were reported, they were not judged relevant due
to ﬂaws in the statistical approach and the Panel came to the conclusion that a cause and effect
relationship had not been shown.
Uncertainty
On the basis of the data presented, the NDA Panel concluded that a cause and effect relationship
had not been established between the consumption of Yestimun® ((1,3)-(1,6)-b-D-glucans from
brewer’s yeast cell wall) and defence against pathogens in the upper respiratory tract. The opinion did
not indicate that such a relation could not be there, but indicated that from the human studies
provided conclusions could not be drawn.
Dietary Reference Values
Introduction
Following a request from the European Commission, the EFSA Panel on dietetic products, nutrition
and allergies (NDA) was asked to deliver a scientiﬁc opinion on dietary references values (DRV) for
vitamin D for the European population.
Vitamin D is a generic term for ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3), which are
formed from their respective provitamins, ergosterol and 7-dehydrocholesterol, following a two-step
reaction involving ultraviolet B (UV-B) irradiation and subsequent thermal isomerisation. Vitamin D2 and
vitamin D3 are present in foods and dietary supplements. Vitamin D3 is also synthesised endogenously in
the skin following exposure to UV-B. However, the properties of sunlight in Europe are not sufﬁcient for
vitamin D3 synthesis during several months each year, resulting in the so called vitamin D winter.
Vitamin D deﬁciency leads to impaired mineralisation of bone due to an inefﬁcient absorption of
dietary calcium and phosphorus, and is associated with an increase in parathormone concentration.
Clinical symptoms of vitamin D deﬁciency manifest as rickets in children and osteomalacia in adults.
Assessment strategy
A balanced diet is one that provides adequate amounts of energy and nutrients for health and
well-being. DRVs comprise a complete set of nutrient reference values, such as lower threshold intake
(LTI), average requirement (AR), population reference intakes (PRI), average intake (AI), and tolerable
upper intake levels (UL).
PRIs can be used for instance as a basis for reference values for food labelling, or for establishing
food-based dietary guidelines (FBDG). FBDG translate nutritional reference values into messages about
foods and diet, which can guide consumers on to what to eat in order to fulﬁl their nutritional
requirements.
Thus, DRVs on vitamin D should ensure that the corresponding requirements be covered in the
European population, without achieving any toxic effect.
Relevance of the evidence/data
Ideally, nutritional requirements are measured in a subset of the target population, for instance
using balance studies to assess the exact amount of a given nutrient, which should be consumed daily
by each individual to offset losses and maintain stores at their optimal level. These data allow deﬁning
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an AR. Taking AR variance into account, it is possible to calculate a PRI, i.e. a level of intake which
should cover the requirements of 97.5% of the population.
In this instance, the Panel considered that available data did not allow deﬁning an AR, hence
calculating a PRI. Instead, the Panel chose to set an AI.
In a ﬁrst step, the Panel searched for biomarker of vitamin D status. Intervention and prospective
observational studies were considered using endpoints related to musculoskeletal health through bone
measurements (BMC, BMD) obtained via different techniques and after an appropriate study duration
(e.g. at least one year), as well as the assessment of osteomalacia or bone fractures. Other health
outcomes were also considered, such as adverse pregnancy-related outcomes, but the example is
restricted to adult males and non-pregnant females.
Although the results were somewhat blurred by the use of different analytical methods, it was
possible to conclude that there is evidence for an increased risk of adverse musculoskeletal health
outcomes at serum 25(OH) concentrations below 50 nmol/l. Thus, the serum concentration of 25(OH)
D can be considered as a surrogate marker of vitamin D status.
Nature and size of the effect
The next step was to assess the relationships between 25(OH)D and vitamin D intakes. In order to
avoid confounding by endogenous synthesis, studies carried out during minimal sun exposure, lasting
for at least 6 weeks, with oral exposure to vitamin D at least twice a week were considered. The
articles which matched eligibility criteria were used to perform a quantitative analysis of the extracted
data through a meta-analytic approach. Background intake was added to the supplemental vitamin D
dose to generate total vitamin D estimates. When the habitual vitamin D intake was not reported,
surrogates were imputed using appropriate age- and sex-speciﬁc mean vitamin D intake values (from
food) from the national nutrition survey relevant to the country in which the study was performed.
Two different models of the dose-response relationship between total vitamin D intake and
plasma/serum 25(OH)D concentration were explored: a linear model and a non-linear model (i.e.
with the natural logarithm transformation of the total intake). Finally, the Panel decided to retain the
non-linear model to better describe the dose-response shape and to be able to include results from
higher dose trials (i.e. up to 50 lg/day).
A number of factors potentially inﬂuencing the dose–response relationship were investigated, in
order to select factors to be included in the ﬁnal model to characterise the high heterogeneity of
results across individual trials. After the inclusion of the ﬁnal set of covariates, the adjusted R2
(proportion of between-study variance explained) of the ﬁnal model was 85%, meaning that the ﬁtted
factors were able to characterise most of the across-trials variability in response. The models were
used to predict the achieved mean serum 25(OH)D concentrations corresponding to total vitamin D
intakes of 5, 10, 15, 20, 50, 100 lg/day and to estimate the total vitamin D intakes that would
achieve serum 25(OH)D concentrations of 50, 40, 30, 25 nmol/l.
A number of sensitivity analyses were also carried out to evaluate whether the ﬁndings were robust
to the assumptions made in the systematic review protocol and the analyses, in particular, on the
background intake imputation process, on eligibility criteria (e.g. fortiﬁed food trials versus supplement
trials); characteristics of participants (e.g. exclusion trials that did not explicitly exclude supplement
users, persons with sun holidays, persons using sunbeds/artiﬁcial UV-B sources or going on sunny
holidays). None of these sensitivity analyses raised serious concerns about the robustness of the
overall analysis.
The Panel considered that the results of this meta-regression analysis could be used to set DRVs
for vitamin D.
Overall relevance taking into account the exposure
The Panel used information obtained from characterising the intake-status relationship for vitamin D
to derive the vitamin D intake to achieve a target serum 25(OH)D concentration of 50 nmol/l. For the
purpose of deriving AIs for vitamin D, the Panel decided to focus on the adjusted model obtained with
data mostly on adults. The estimates from that model were derived based on all covariates.
In the adjusted model, the total intake estimated to achieve a serum 25(OH)D concentration of
50 nmol/l, as identiﬁed by the lower limit of the 95% PI, is 16.1 lg/day. Equally, at a vitamin D intake
of 15 lg/day, the predicted mean serum 25(OH)D concentration is 63 nmol/l (95% CI: 58–69 nmol/l),
with a predicted value at the lower limit of the 95% PI of 49 nmol/l.
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Predicted interval (PI) in the context of a meta-regression analysis illustrates the uncertainty about
the true mean response predicted in a future study. Moreover, 95% PI constitutes an approximation of
the interval that would include 95% of all individual responses from the populations included in
previous and future studies, as it refers to the population of mean responses. The extent of this
approximation could not be quantiﬁed.
The Panel therefore set an AI for vitamin D for adults at 15 lg/day, considering that, at this intake,
the majority of the adult population will achieve the target serum 25(OH)D concentration near or
above 50 nmol/L. The Panel decided not to set speciﬁc AIs for ‘younger’ or ‘older’ adults, because
there was no evidence of a signiﬁcant difference in absorption capacity between ‘younger’ and ‘older’
adults and the majority of the studies used to set the target value for 25(OH)D concentration were
carried out in ‘older adults’.
The unadjusted model can be also taken into account as it encompasses the whole heterogeneity
across trials. In the unadjusted model, considering a vitamin D intake of 15 lg/day, the lower limit of
the 95% PI is 34 nmol/L. This value is above the concentrations that have been observed in relation to
overt adverse health outcomes (osteomalacia, calcium absorption). Considering a vitamin D intake of
15 lg/day, the upper limit of the 95% PI is 91 nmol/L in the unadjusted model (and 78 nmol/L in the
adjusted model). These values are in the physiological range (EFSA NDA Panel, 2013).
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Annex H – PLH
The EU plant health legislation aims to protect crops, fruits, vegetables, ﬂowers, ornamentals and
forests from harmful pests and diseases (harmful organisms) by preventing their introduction into the
EU or their spread within the EU. This aim helps to:
• contribute to sustainable agricultural and horticultural production through plant health
protection;
• contribute to the protection of public and private green spaces, forests and the natural
landscape.
The Council Directive 2000/29/EC5 provides the basis for this aim. The general principles are based
upon provisions laid down in the International Plant Protection Convention (IPPC, 2007).
Directive 2000/29/EC is supported by further legislation in the form of a number of Control
Directives and Emergency Measures.
In order to meet the aims of the regulation, the EU:
• regulates the introduction of plants and plant products into the EU from countries outside the
EU;
• regulates the movement of plants and plant products within the EU;
• imposes eradication and containment measures in case of outbreaks, and co-ﬁnances them;
• places obligations on countries outside the EU which want to export plants or plant products to
the EU.
The Panel on Plant Health (PLH) provides independent scientiﬁc advice on the risk posed by plant
pests which can cause harm to plants, plant products or biodiversity in the EU. The Panel reviews and
assesses those risks with regard to the safety and security of the food chain.
The EFSA plant health panel supports commission decisions on plant health by making scientiﬁcally
based pest risk assessments. The risk assessment follows the structure agreed by the Secretariat of the
International Plant Protection Convention (2007). The PLH panel has outlined its procedures in guidance
documents on the pest risk assessment (EFSA PLH Panel, 2010) and the evaluation of risk reduction
options (EFSA PLH Panel, 2012). The panel is currently working on a framework for a risk analysis that
is quantitative. Aims of introducing a quantitative approach are to increase consistency, transparency
and objectivity. In this new approach, the steps in the assessment are elaborated quantitatively. The
steps are: (1) pest entry into the EU, (2) pest establishment in the EU, (3) pest spread within the EU,
and (4) impact assessment. These steps are cumulative, as there will be no impacts without the
previous steps taking place. When compared to the risk assessment for toxic or beneﬁcial compounds,
the ﬁrst three steps are similar to exposure, while the impact assessment has similarity to the
dose-response relationship in toxicological studies. Indeed, Robinet et al. (2016) use the term
‘exposure’ to describe the contact rate of native European trees with propagules of the pathogenic
fungus Ceratocystis fagacearum that can enter Europe on wood imported from the United States.
The current example is based on an ongoing risk assessment on the potato rot nematode,
Ditylenchus destructor. This risk assessment was elaborated following the new quantitative approach.
The opinion is in preparation for possible adoption by the EFSA plant health panel in September 2016.
In the pest risk assessment on Ditylenchus destructor, the panel focused the assessment of entry,
establishment, spread and impact on two crop species: potato (Solanum tuberosum) and tulip (Tulipa
spp.). The choice of these two species was based on considerations of relevance as potato and tulip
were judged, based on production areas and trade ﬂows, to be the most relevant pathways for
introduction and spread of this nematode with planting material, and also for the materialisation of
impacts in crop production. Other ﬂower bulb species could also be vectors for entry and spread, but
they were not considered because the trade volumes are much smaller than those of tulips. Impacts in
other bulbs species are also expected to be much smaller than those that could occur in tulips because
of smaller production areas.
A modelling approach was used to estimate entry, spread and impact quantitatively. Trade data
were used for assessing import volumes. Literature and expert judgement were used to estimate
model parameters, taking into account uncertainty. Special attention was paid to the evaluation of risk
reduction options for planting material, treatment of ﬂower bulbs before trading, and treatment of soil
prior to planting of potato.
5 http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2000:169:0001:0112:EN:PDF
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A baseline scenario with current pest-speciﬁc phytosanitary regulations was compared with
alternative scenarios without those speciﬁc regulations or with additional risk reduction options.
Further information was provided on the host range of D. destructor and on survival of the pest in soil
in the absence of hosts.
The Panel concluded that the entry of D. destructor with planting material from third countries is
quite small compared to the yearly intra-EU spread of this nematode with planting material. Changes
in pest speciﬁc regulations have little inﬂuence on entry of the pest. It was also concluded that the
whole pest risk assessment area is suitable for establishment of D. destructor, but there is insufﬁcient
information to make a statement on the persistence of newly introduced populations. Impacts of this
nematode on the quantity and quality of potato production are considered negligible. The Panel also
considers the impact of this nematode on ﬂower bulb production in the EU as very low.
Assessment strategy
The Commission asked EFSA to assess various aspects of the risks of the potato rot nematode
Ditylenchus destructor to agriculture in the EU. The PLH panel decided to conduct a pest risk
assessment according to the framework provided by Secretariat of the International Plant Protection
Convention (2007), entailing an assessment of the risks of entry, establishment, spread and impact.
The nematode is already present within the EU, albeit sporadically, and it is not entirely clear a priori
whether additional entry is of relevance for the impacts of this nematode. The Panel developed a
model for entry, establishment, spread and impact to assess the relative importance of entry of this
nematode with trade from third countries and its spread within Europe in intra-European trade of plant
products.
Evidence/data needed to address the question
To assess this question, information is needed on trade ﬂows in plant products that can serve as a
vector. Both the trade-ﬂows from Third countries (i.c. Canada and Switzerland that have presence of
this nematode but can import under certain restrictions) are considered, and those within Europe.
Furthermore, information is needed on the prevalence of the nematode in the trade ﬂows.
Furthermore, information is needed on the host plants of the nematode, and the impact caused on
those hosts. In addition, information is needed on the conditions for establishment. The panel focused
the assessment on seed potato and ﬂower bulbs, which constitute the most important plant product
that can serve as a vector. Furthermore, ware potatoes and many ﬂower bulb species are hosts and
can suffer damage.
Data evaluation
Adequate data are available on the international trade in seed potatoes. However, no adequate
data are available on the trade in ﬂower bulbs because the data in Eurostat are not recorded at a
sufﬁcient level of resolution between species. Therefore, trade in host species and non-host species
cannot be well distinguished. Data on production areas of seed potatoes across the EU are good. Data
on production areas of ﬂower bulbs are adequate.
Information on the prevalence of the nematode in the EU and in third countries is extremely
sparse. Only vague descriptions are available like ‘present in all parts of the area where host crops are
grown’, ‘present, restricted distribution’, ‘present, few occurrences’, ‘present’ and ‘absent’. These terms
were interpreted by the panel in terms of proportion of production ﬁelds infested with the nematode
and proportion of planting material harvested from infested ﬁelds that carry the nematode. This
interpretation is a reason for large uncertainties in the estimates of the ﬂow of infested planting
material. Furthermore, the Panel made assessments of survival of the nematode in trade ﬂows, and of
the efﬁcacy of import and export inspection and of certiﬁcation schemes to reduce or limit the levels of
infestation of plant product with the nematode. Due to lack of pertinent data, these assessments were
also quite uncertain.
Relevance of the agent
The potato rot nematode D. destructor causes rots in root crops and bulbous crops. The species is
well characterised and the potential damaging effects are also well characterised. If uncontrolled, this
nematode can multiply, spread and cause substantial damage. However, with current phytosanitary
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measures for containing the spread with plant products, and efﬁcient weed control in crops, reducing
the number of potential hosts for the nematode, the impact of this nematode under current conditions
is minor.
Nematodes can live in tubers, bulbs and rhizomes, and they can be spread with trade in such
products over practically unlimited distance. Infested planting material is the main pathway for spread.
Autonomous spread by nematodes is not practically relevant. Spread by farm machinery is possible but
is still a short distance spread (mostly within ﬁeld or farm). There is no known minimum number of
nematodes that is required to cause establishment or infestation of a plant.
Relevance of the subject
The Panel made the assessment focusing on seed potatoes and tulip bulbs. Seed potatoes are the
most important carrier for the nematode. Flower bulbs are also potentially important, and the trade in
the host species tulip is the largest amongst ﬂower bulbs. Both potato and tulip suffer damage if
infested.
Relevance of the effect
This nematode can cause considerable damage if there are not measures in place to prevent this
damage.
Relevance of the conditions
The assessment was carried out considering common practices in current trade and crop cultivation
in Europe. These conditions are fully relevant.
Overall conclusion
This nematode is present in two-thirds of the EU Member States, but is currently of minor
importance in Europe as current measures and agricultural practices are effective in limiting spread
and impact. Lifting pest-speciﬁc measures is not expected to change this because certiﬁcation of
planting material of potato and ﬂower bulbs needs to meet quality criteria that would effectively limit
the presence of this agent.
Uncertainty
The key uncertainty in the assessment is the current distribution. There are no reports on
structured surveys in the EU or in third countries to quantify at relevant spatial scales the prevalence
of this nematode. There is thus no relevant information available on: (1) the presence in geographic
areas below the level of member state, (2) proportion of infested area ﬁelds in those geographic areas
in which the nematode occurs, and (3) proportion of infested planting material harvested from infested
ﬁelds. The lack of quantitative information on the multi-scale presence of the organism is a great
impediment to making the assessment. Instead of basing its parameter estimates for the model on
data, the Panel had to resort to expert judgements. In the assessment, the Panel made use of
stochastic simulations and the resulting distributions of outcomes show variability over four orders of
magnitude (EFSA PLH Panel, 2016).
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Annex I – PPR
PESTICIDES HAVING EFFECTS ON THE THYROID HORMONE SYSTEM
In the MRL regulation 396/2005, it was laid down that account should be taken of ‘the possible
presence of pesticide residues arising from sources other than current plant protection uses of active
substances, and their known cumulative and synergistic effects, when the methods to assess such
effects are available’.
Then, in the later pesticide regulation 1107/2009, the precautionary principle applies and therefore
before placing active substances in plant protection products on the market it should be demonstrated
that they do not have any harmful effect on humans.
However, not only the single active substance should not have harmful effects but should also take
account of effects from mixtures of pesticides. Thus, the regulation reads ‘shall have no immediate or
delayed harmful effect on human health, including that of vulnerable groups, or animal health, directly
or through drinking water (taking into account substances resulting from water treatment), food, feed
or air, or consequences in the workplace or through other indirect effects, taking into account known
cumulative and synergistic effects…’.
This would be applicable not only for dietary risk assessment but also non-dietary (operators,
workers, bystanders and residents).
EFSA was in accordance with the regulation commissioned to develop the methodology for carrying
out cumulative risk assessment in regard to MRL-setting and launched this work in 2006 with a
scientiﬁc colloquium followed by subsequent opinions, amongst the ‘Scientiﬁc opinion on the
identiﬁcation of pesticides to be included in cumulative assessment groups on the basis of their
toxicological proﬁle’. In the opinion, a methodology for grouping was developed and two cases where
elaborated on; Pesticides having effects on the nervous system and pesticides having effects on the
thyroid system. A total of nearly 300 pesticide dossiers were evaluated for these two cases.
Assessment strategy
In this case, two problem formulations are being answered on the basis of the same data sets.
1) For the single pesticidal active substance assessment, establish no observed adverse effect
levels (NOAELs) in case of effects on the thyroid system is a critical effect.
2) Identiﬁcation of pesticides to be included in cumulative assessment groups (CAG’s) on the
basis of their toxicological proﬁle (hazard assessment) – in this case effects on the thyroid
system – and establishing NO(A)EL’s in this context.
The establishment of the critical effect, the NOAEL for this effect and deriving reference doses
(AOEL, ADI, ARfD) is to protect the human population exposed to the pesticide when applied and to
the protect the population being exposed via all routes of exposure.
The grouping of the pesticides into CAG’s was developed to support the regulatory MRL-setting and
as such the target population is the European Consumer.
Agents Effects Subjects Conditions
Single active substance Effects on the
thyroid system
The human
population
Dietary and non-dietary exposure
Establishment of NOAEL in Subchronic
when effect on the thyroid is a critical
effect – chronic exposure
Cumulative Assessment
Groups of active substances
(CAGs)
The human
population
Dietary exposure
Establishment of NO(A)EL in
subchronic – chronic exposure
Data collection and selection of the biologically relevant data
For the standard assessment of pesticidal active substances, the regulation speciﬁes extensive data
requirements in regard to mammalian toxicity (exposure usually by the oral route) on several species
and exposure duration (from sub-acute to chronic).
In addition to the regulatory studies, where data from the scientiﬁc literature on pesticides and
their effects on the thyroid system were available this was taken into account to support mechanistic
understanding of the effect.
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No speciﬁc data requirements are set in the regulations for the purpose of grouping of pesticides
into CAG’s.
For assessment of the histopathological ﬁndings, these are generally classiﬁed according to
qualitative criteria and the data are presented as number of animals affected within a dose group.
Numerical results, should according to the relevant OECD guideline, be ‘evaluated by an appropriate
and generally acceptable statistical method’. As the data base for grouping of pesticides for having
effects on the thyroid system consists of a little less than 300 pesticide dossiers, the statistical
methods applied will of course be different from study to study. But in all cases they have been
assessed and peer-reviewed and NOAEL’s have been established for the single substance evaluation.
The power of the studies would also be very varied going from the very low-powered dog study, with
usually only four animals/sex per group, to more well-powered rodent students with 20 animals/sex per
group, and in case of carcinogenic effects, there are 50 animals/sex per group. Normally, the power of a
given study for the different endpoints investigated is not stated.
On studies in dog, results that are not statistically signiﬁcant are also be considered for their
biological signiﬁcance, and individual values are been taken into account. It is considered that the
statistical signiﬁcance in the dog studies might not be reliable due to the high inter-individual variability.
Relevance of the effects for humans
For detailed description of the thyroid system, see Miller (2009) and the following ﬁgure6 showing
where chemicals might pertubate the thyroid system.
When declines in circulating and tissue hormone levels occur, feedback mechanisms of the
hypothalamic–pituitary–thyroid axis would result in increased secretion of thyroid stimulating hormone
(TSH) and subsequently the follicular cells would increase the secretion of T3/T4 and thus levels of
bioavailable T3/T4 would be re-adjusted.
Alterations in circulating bioavailable thyroid hormone levels may have serious impact on other
organs or organ systems besides the thyroid itself also in humans, particularly if perturbations occur
during critical windows of development’ (EFSA, 2013a,b).
Figure I.1: Thyroid hormone system with potential targets for disruption by xenobiotics (blue). NIS,
sodium/iodide symporter; TBG, thyroid hormone-binding globulin; TH, thyroid hormone
(T3/T4); T3, triiodothyronine; T4, thyroxine; TRH, thyrotropin-releasing hormone; TSH,
thyroid-stimulating hormone; TTR, transthyretin; UDGTs, UDP-gluuronosyl transferases
(Miller et al., 2009)
6 Reproduced with permissions form Environmental Health Perspectives.
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And further the PPR panel noted that ‘Any degree of thyroid disruption that lowers TH levels on a
population basis should be considered a biomarker of increased risk of adverse outcomes, which may have
important societal outcomes’ (Miller et al., 2009) (EFSA, 2013a,b). So as such adverse effects/effects
on the thyroid system are considered relevant for the human population.
Is the effect in itself a(n) adverse/beneﬁcial effect?
Single pesticide evaluation of adverse effects on the thyroid hormone system
When evaluating adverse effect on the thyroid, physiological changes preceding adverse
manifestations in target organs (changes in circulating thyroid hormone levels) and indicators of
perturbation of thyroid hormone homeostasis (e.g. elevation of TSH based or thyroid enlargement) would
not be regarded as adverse when establishing the NOAEL for thyroid effects in a study. The assumption is
that as a consequence of changes in circulating and tissue thyroid hormone levels, compensatory
mechanisms including activation of the hypothalamic-pituitary-thyroid axis following a decline in
peripheral thyroid hormone levels with subsequent increased production and secretion of TSH (thyroid
stimulating hormone) may be expected to result in adjustment of bioavailable thyroid hormone levels.
Thus, changes in circulating or tissue T3/T4 hormone levels would be transient (EFSA, 2013a,b).
Effects on the thyroid hormone system in regard to grouping for CRA
In regard to grouping of pesticides for cumulative risk assessment other considerations were also
taken into account. It was noted that; ‘For the evaluation of the common toxicological proﬁle for
assignment of an active substance to a CAG, different indicators may be taken into account, which could
comprise downstream endpoints with obviously adverse target organ effects or upstream precursor
effects e.g. a decrease in T4 levels, that may eventually lead to manifestation of an adverse organ effect.
In the context of CRA, it is therefore proposed to also consider the physiological change preceding
adverse manifestations in target organs (changes in circulating thyroid hormone levels) and indicators
of perturbation of thyroid hormone homeostasis (e.g. elevation of TSH or thyroid enlargement), to be
of relevance for deﬁnition of cumulative assessment groups’. (EFSA, 2013a,b)
So accordingly, the following effects were considered as speciﬁc effects and indicators relevant for
grouping: changes in serum T3/T4, changes in serum TSH, follicular cell hyperplasia/hypertrophy and/or
increased thyroid weight and thyroid tumours and the speciﬁc NOAEL’s were established.
Relevance of the conditions
It is mandatory to investigate effects on the thyroid system in pesticide active substance dossiers.
The effects are always addressed after 90-day exposure in rodents – usually rats – and dogs. The
following endpoints are mandatory, histopathological evaluation of the thyroid and pituitary, while
estimation of hormones (T3, T4 and TSH) is optional (case by case). Also, histological evaluation of
the thyroid glands and the pituitary is conducted in the mandatory carcinogenicity studies in rats and
mice. All species are considered relevant for humans. The duration of exposure is considered relevant
for chronic dietary exposure and non-dietary exposure.
Hazard characterisation by oral exposure is considered relevant for dietary as well as non-dietary
exposure (mainly dermal). For pesticides where the inhalatory exposure is the main route – such
studies might be required for repeated dose studier. However, this is rare.
Uncertainties
As discussed above, the rat is considered a very sensitive proxy in regard to effects on the thyroid
system. Therefore, the PPR panel noted in regard to follicular tumours; ‘concerning effects on the
thyroid itself, prolonged enhanced secretion by the pituitary of TSH as a response to decreased
circulating thyroid hormone levels in rat studies leads to thyroid follicular cell hypertrophy and
hyperplasia, which eventually may act as a promoting factor in the development of benign and
malignant follicular cell tumours. Although compensatory mechanisms based on feedback loops within
the hypothalamic-pituitary thyroid axis are also operative in humans from a qualitative point of view, it
appears that humans are quantitatively less susceptible to follicular cell tumour formation resulting
from thyroid hormone system imbalance than rats, based on marked quantitative differences in
kinetics of circulating thyroid hormones and in the extent of response to changes in thyroid hormone
levels (Dellarco et al., 2006)’.
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Conclusion
The same effects in regard to effect on the thyroid hormone system, namely statistical signiﬁcant
changes in serum T3/T4 and or TSH would be assessed differently. In the single substance evaluation,
such changes, although clearly treatment related, would not be considered as adverse effects if they
are not accompanied by adverse tissue manifestations. In regard to grouping based on toxicological
proﬁle for cumulative risk assessment, the effects are considered as relevant speciﬁc indicative effects
on the thyroid system. Thus, different NO(A)EL’s could be established based on the same data set and
therefore, in different regulatory contexts, the same effect, although being regarded as biologically
relevant in both settings, the impact on regulatory decision making is different.
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Annex J – CONTAM Panel
Human health risk assessment of Cadmium in food:
Scientiﬁc Opinion of the Panel on Contaminants in the Food Chain; The
EFSA Journal (2009) 980, 1–139
Assessment strategy
Cadmium (Cd) is a heavy metal found as an environmental contaminant, both through natural
occurrence and from industrial and agricultural sources. Foodstuffs are the main source of cadmium
exposure for the non-smoking general population. Cadmium absorption after dietary exposure in
humans is relatively low (3–5%) but cadmium is efﬁciently retained in the kidney and liver in the
human body, with a very long biological half-life ranging from 10 to 30 years.
For the purpose of the guidance and although the scientiﬁc assessment of cadmium had a broader
content, the example below focuses only on one effect.
The kidney is the critical target organ for dietary exposure to cadmium and renal damage is
characterised by cadmium accumulation in convoluted proximal tubules, thereby causing cell
dysfunction and damage. The earliest signs of tubular toxicity are, respectively, decreased tubular
reabsorption (increased excretion) of low molecular weight proteins (LMWP) and increased excretion of
markers of cell shedding.
Problem: Characterise critical effect for the purpose of deriving a Health based guidance value
Identiﬁcation
of the Agents
Identiﬁcation of the Effects
Identiﬁcation
of the Subjects
Identiﬁcation of the Conditions
Cadmium Critical effect: Kidney damage
(cell dysfunction and damage of
convoluted proximal tubules)
Humans Biomarkers (decreased tubular
reabsorption (increased excretion) of
low molecular weight proteins (LMWP)
and increased excretion of markers of
cell shedding)
Data collection/data evaluation for each data set
The availability of quantitative human data for both toxicokinetics (TK) and toxicodynamics (TD)
provides relevant data for hazard identiﬁcation and characterisation without the need to use animal
data.
Data evaluation (Biological Relevance)
Cadmium is bioaccumulating due to very slow renal excretion (TK), leading to excretion of
biomarkers of kidney damage (TD).
Biological Relevance of biomarker of proximal tubular dysfunction
Is the effect in itself a(n) adverse/beneﬁcial effect?
The CONTAM Panel based its assessment on the use of the low molecular weight protein (LMWP)
b-2-microglobuline (B2M) in urine as a biomarker of Cd-induced tubular toxicity. Increased excretion of
B2M is not per se associated with any objective symptom or disease. Outcome: B2M is not in itself an
adverse effect.
Is the effect essentially linked to a(n) adverse/beneﬁcial outcome?
The urinary excretion of LMWPs and the activity of some enzymes (mainly N-acetyl-beta-
glucosaminidase (NAG)) in urine have been, respectively, used to assess tubular dysfunction and cell
damage; Urinary b-2-microglobulin (B2M) has been widely used as an indicator. Outcome: B2M is
essentially linked to an adverse outcome
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Relevant size of the effect?
In occupational exposed subjects, adverse effects of cadmium on the kidney were observed at
urinary levels of cadmium ranging from 1.1 to 15 lg/g creatinine; abnormal levels of B2M were found
in the urine of workers with urinary cadmium levels greater than 1.5 lg/g creatinine.
Based on studies on the clinical relevance of urinary B2M excretion, tubular damage and renal
function and damage the Contam Panel chose cut-off levels associated with renal protection and
irreversible kidney damage (see page 71, EFSA Journal (2009) 980, 71–139). As an indication of
abnormality, a value of 1,000 lg B2M/g creatinine was set as a high-level criterion. B2M excretion
levels above this limit are likely to be irreversible kidney damage.
As a lower and more protective cut-off level, a value of 300 lg B2M/g creatinine was chosen.
Exceeding the biological cut-off of 300 lg/g creatinine for B2M has been associated with an
accelerated decline of renal function associated with aging together with increased mortality.
Statistically based cut-off criteria corresponding to the 95th percentile of the B2M distribution at
background urinary cadmium concentrations were also calculated. The statistically based cut-offs for
the whole populations and for subjects over 50 years were 211 and 374 lg B2M/g creatinine,
respectively.
BMDs and BMDLs at various cut-offs leading to extra risks of 5% in the total population, and
non-occupationally exposed subjects above 50 years of age were calculated.
Calculations of BMDs and BMDLs
Relevance of the conditions
The relevance of the different BMDL5 calculated for risk assessment of the whole population were
evaluated by the CONTAM Panel
Taking into account the slightly higher values for the subjects over 50 years and the range of the
BMDL5 results for the statistical and the biological cut-off limit of 300 lg B2M/g creatinine, the
CONTAM Panel selected an overall group-based BMDL5 of 4 lg cadmium/g creatinine.
The use of 300 g B2M/g creatinine as critical effect of cadmium exposure to base the risk
assessment leads to a possible overestimation of the risk, but it allows protecting the most sensitive
groups of the population.
To account for inter-individual variability in cadmium concentration within groups, not explicitly
accounted for in the BMD modelling (i.e. when calculating the lower one-sided 95%-conﬁdence bound
for an extra risk of 5% of producing a speciﬁed change in the urinary level of the B2M, denoted
BMDL5), the CONTAM Panel modiﬁed the BMDL5 value using a chemical speciﬁc adjustment factor
(CSAF) for cadmium based on the estimated variance of within group cadmium concentration. After
adjustment, the CONTAM Panel identiﬁed a critical cadmium concentration of 1 lg cadmium/g
creatinine in urine as a modiﬁed reference point (RP) on which to base a health-based guidance value
(HBGV) of cadmium dietary intake.
Converting the RP to an intake value and derive a HBGV for Cd
Subsequently, a one-compartment population TK model was ﬁtted to 680 paired data of cadmium
intake and urinary cadmium concentrations from the Swedish Mammography Cohort study
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(Amzal et al., 2009). This TK model showed that a dietary intake of no greater than about 2.5 lg/kg
bw cadmium per week would prevent 95% of the Caucasian population from being above the modiﬁed
RP of 1 lg cadmium/g creatinine in urine after 50 years of exposure (EFSA, 2009b). In order to
remain below this modiﬁed RP, it was calculated that the average daily dietary cadmium intake should
not exceed 0.36 lg/kg bw, and this daily intake was used to derive the TWI of 2.5 lg/kg bw.
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Annex K – Environmental Risk Assessment
In environmental risk assessment, the protection goal is normally based on protecting populations.
In some cases, it is also based on individuals, for instance for all vertebrates. Sometimes the
protection goal is a function, for instance nitriﬁcation, and sometimes it includes even behaviour, e.g.
for bees and vertebrates.
For example, in the Avian Reproductive Test (OECD 206) the following endpoints must be assessed:
• Frequency, duration and description of signs of toxicity, along with severity, numbers affected
and any remissions
• Food consumption and body weight for adults and juveniles
• Details of gross pathological examinations
• Results of residue analysis (if performed)
• Egg production – number of eggs laid per hen (10 weeks)
• Percentage of cracked eggs
• Viability (per cent viable embryos of eggs set)
• Hatchability (per cent hatching of eggs set)
• Percentage of hatchlings that survive to 14 days
• Number of 14 day old survivors per hen
• Eggshell thickness (mm)
The test should be carried out with a minimum of three dietary concentrations of the test
substance. The concentrations to be used should be based upon the results of a dietary LC50 test
(OECD 205). The highest concentration should approximately be one half of the LC10. Lower
concentrations should be geometrically spaced at fractions of the highest dose (e.g. 1/6 and 1/36 of
the highest dose).
As a consequence of this design, the power for each endpoint is different. For some endpoints the
power will be very weak and some others strong and they will vary between compounds and over
time.
All endpoints are in principle assumed to be relevant when populations are the protection goal. The
hazard assessment of the bold printed endpoints above is based on a NOEC, i.e. the highest tested
concentration in which the values for the observed effect are not signiﬁcant different from the control.
Of all other observations, the risk assessor has to consider whether these effects could inﬂuence the
survival of the population.
Although an endpoint is statistically signiﬁcantly different from the control it may not be biologically
relevant. In order to determine the biological relevance of an effect it should be considered whether
the effect could lead to a functional deﬁcit later on in the study, e.g. if a reduction in the weight of
pups at birth leads to a decrease in level of survival. If not, then the effect may not be biologically
relevant, however if there is a carry-over of effects into the number of survivors, it can be considered
biologically relevant.
Example involving egg shell thickness and cracked eggs
As stated above, not all outcomes of the test are biological relevant, for instance if the lowest
observed effect concentrations (LOEC) for egg shell thinning is 3% than it is generally believed that
the NOEC does not have a biological relevance. It is believed that the biological relevant percentage of
egg shell thinning starts with 18% (Blus, 2003; EFSA, 2009a,b,c). The BMD dose equivalent to 18%
effect can be calculated with an appropriate method. This BMD can be considered as the ‘NOEC’ for
cracked eggs (see ﬁgure below).
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In many cases, it will be difﬁcult to point out what the biological relevant threshold of an endpoint
will be. A tool that can be used is to run legislative acceptable models and to assess at which
percentage a population will not be able to recover any more or when a population suffers to an
unacceptable degree and to include in this assessment the uncertainty around the outcome.
In many cases, it will be difﬁcult to determine what the biological relevant cut-off of an endpoint
will be.
Taking a conservative approach the ‘NOEC’ for cracked eggs would be a good starting point for the
risk assessment, but it is probably not the cut-off value at which a population will start to show signs
of decreased ability to survive.
A tool that can be used is to run legislative acceptable models and to assess at which percentage a
population will not be able to recover any more or when a population suffers to an unacceptable
degree and to include in this assessment the uncertainty around the outcome.
In Topping and Luttik (2017), an example is provided how such a biological relevant endpoint can
be assessed. For Denmark, 10 skylark scenarios were developed to cover most of the agricultural
landscape of the country. According to the model simulations 10% or less cracked eggs does not affect
any of the skylark populations in the long term. Based on this outcome, a BMD analysis based on a
BMR of 10% cracked eggs can be determined according to the dose–response relationship between
cracked eggs and egg shell thinning and this value could be used as the biological relevant endpoint
size.
An alternative option would be to allow some level of population effect. In the model used for
skylarks in Denmark, one could exclude the most sensitive scenario and calculate the BMR based on
the next most sensitive landscape. This would result in a higher BMR and a higher BMDL. This
approach would be similar to that in exposure modelling using a 90th percentile of the exposure
distribution, which means that in 10% of the cases a higher exposure is expected. In this case, this
would mean a BMR of 20% as the rest of the scenarios do not show at the 20% egg cracking level
any long-term effects on the populations of skylarks. Although a 20% cracking rate for the most
sensitive population over the simulation period would only result in small long-term population
declines, this would probably be unacceptable.
The ﬁnal decision on which BMR to use is a complicated one related to protection goals taking into
account social and political realities and set by the risk manager, and scientiﬁc evidence available for
the assessment. There is an argument for adopting the more conservative approach based on the
uncertainty surrounding the effect of potential exposure to multiple pesticides, which is not currently
assessed following EFSA guidance. In contrast, the need of effective pest control to support
agricultural production argues for less conservatism.
Another approach is to include recovery in the risk assessment, which is for instance an option in
aquatic risk assessment (not ﬁsh or amphibians) and terrestrial risk assessment for invertebrates. In
Figure K.1: Relation between egg shell thickness (orange line) and cracked eggs (red line). The
dashed line is the line for effecting the reproduction of a bird species (e.g. when is the
number of cracked eggs too much for maintaining a stable population)
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the aquatic ecosystem, a compound can be allowed on the market when recovery is seen within a
period of 8 weeks but only when all important organism groups are included in the mesocosm
experiment (see opinion on recovery, EFSA, 2013a,b, 2016a–e).
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